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1. Introduction 
The lack or incompleteness of evidence of the efficacy and safety of drugs used in children 
has been a growing concern in the recent past. The great majority of drugs prescribed to 
children are often given either on an unlicensed or an “off label” basis simply by 
extrapolating data for adults and without conducting any paediatric clinical, 
pharmacokinetics, dose finding, or formulation studies in the paediatric population. The 
paediatric pharmaceutical repertoire therefore comprised pills too large to swallow and 
extemporaneous formulations containing excipients unsafe or unpalatable to children. 
Diseases in children, however, are often different from their adult equivalents, and the 
processes underlying growth and development might lead to a different effect or an adverse 
drug reaction unseen in adults. 
The health and, therefore, quality of life of the children in Europe suffer from a lack of 
testing and authorisation of medicines for their use. It means that children are “orphans” of 
appropriate medicinal products and children continue to be exposed to risks, and at the 
same time miss out on therapeutic advances. 
This is particularly ironic considering that our modern system of medicines regulation, that 
ensures the high standards of safety, quality and efficacy of medicinal products for use in 
adults, was developed primarily in response to therapeutic disasters, or “drug 
catastrophes”, that occurred in children in the past ( such as the numerous cases of icterus 
induced by sulphanilamide which occurred in 1937 and the well-known phocomelia caused 
by thalidomide in the 1960s). 
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For these reasons, the development of regulations and the adoption of stringent criteria on 
quality, safety and efficacy medicinal products used in the paediatric population have been 
enforced and led in January 2007 to the introduction in the European Union (EU) of the 
“Paediatric Regulation” (European Parliament and the Council of the European Union, 
2006a, 2006b) governing the development and authorisation of medicines for use in children 
aged 0 to less than 18 years. The Paediatric Regulation is the latest in a number of 
incremental regulatory steps to improve public health for children through increasing 
research, information and availability of medicines. It brings in many new tasks and 
responsibilities for the European Medicines Agency (EMA), chief of which is the creation 
and operation of an ad hoc Paediatric Committee (PDCO) within the EMA to provide 
objective scientific opinions on any development plan for medicines for use in children. 
Since the entry into force of the Paediatric Regulation, the regulatory environment for 
paediatric medicines has dramatically changed, a marked “paediatric revolution” aimed at 
improving the health of children in the EU took place and pharmaceutical companies have 
been faced with a number of measures, obligations and incentives. 
2. The Paediatric Regulation 
2.1 Objectives 
The objective of the Paediatric Regulation is to improve the health of children in Europe by 
increasing and facilitating the development and availability of medicines for children aged 0 to 
less than 18 years, that means changing the way in which medicines are developed. Increasing 
the development of medicines for children is to be reached by ensuring that those medicines 
are subject of high quality, ethically researched and authorised appropriately in the relevant 
population subsets including the neonates, to avoid, at the same time, unnecessary clinical 
trials in children and not delaying the authorization of medicines for the adult population.  
The new key element of the Paediatric Regulation is the early involvement of a 
pharmaceutical company in the research and development programme of a medicinal 
product by the requirement to consider the needs of the paediatric population, also in terms 
of age-appropriate formulations, according to a Paediatric Investigation Plan (PIP) that 
describes the paediatric development (quality, non clinical and clinical aspects) and all 
adopted measures necessary to investigate the medicine in the paediatric population. The 
PIP has to be agreed with an ad hoc committee of experts, namely the Paediatric Committee. 
In case that a) the specific medicinal product or class of medicinal products is likely to be 
ineffective or unsafe in part or all of the paediatric population, b) the disease or condition for 
which the specific medicinal product or class is intended occurs only in adult populations, 
or c) the specific medicinal product does not represent a significant therapeutic benefit over 
existing treatments, it is possible to apply for a waiver. The Paediatric Regulation also 
foresees the opportunity to request a deferral thus avoiding the delay of the authorisation 
for other populations. A deferral allows the postponement of the initiation or completion of 
some or all of the measures set out in PIP, such as the completion of trials, but not the delay 
in the submission of the PIP itself.  
2.2 Obligations and incentives 
The Paediatric Regulation is the first piece of European legislation that requires the 
pharmaceutical industry to develop medicines for use in children through a system of 
obligations and incentives, depending on the type of medicinal product concerned.  
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For medicinal products not yet authorised in the EU, according to article 7 of the Regulation, 
there is an obligation to include the results of studies (conducted in compliance with an 
agreed PIP), unless a waiver or a deferral was granted by the PDCO, for the validation of a 
marketing authorisation application for adult and paediatric medicines.  
For authorised products protected by a supplementary protection certificate, or by a patent eligible for 
a supplementary protection certificate, according to article 8 of the Regulation, there is an 
obligation to include either the results of studies (conducted in compliance with an agreed 
PIP), unless a waiver or a deferral was granted by the PDCO, in applications for variations 
or extensions (of an existing marketing authorisation) concerning a new indication, 
pharmaceutical form or route of administration.  
The compliance with such obligations allows pharmaceutical companies to benefit 
incentives and rewards, aimed at encouraging the development of paediatric medicines. 
Once authorisation is obtained in all EU Member States and study results (whether negative 
or positive) are incorporated into the product information (SPC), the pharmaceutical 
company grants rewards and incentives. 
In details when an agreed PIP is completed and all the information has been submitted to 
the regulatory authorities, the medicinal product, falling under article 7 or 8 of the 
Regulation, will be granted an extra 6 months patent protection (extension of the duration of 
its Supplementary Protection Certificate [SPC]). This extension will be granted whether or 
not the data support a paediatric indication. 
For orphan medicinal products the incentive takes the form of an extra two years market 
exclusivity. 
The Regulation also establishes a new type of marketing authorisation, called the paediatric 
use marketing authorisation (PUMA), intended to stimulate the development of off-patent 
products for use in the paediatric population. The PUMA is the specific instrument created 
by the Regulation aimed at stimulation the development of off patent drugs which represent 
a still unmet need in paediatrics, since most of these compounds widely used daily in 
children of all age groups, have not been adequately tested in the paediatric population. The 
Paediatric Regulation includes provisions for funding of research into off-patent medicines 
(Community Framework Programmes for Research, Technological Development and 
Demonstration Activities or any other Community initiatives for the funding of research). 
Public funding is necessary as off-patent medicines are of little commercial interest for 
pharmaceutical companies. 
2.3 The Paediatric Investigation plan 
As described above, the central key instrument of the Paediatric Regulation is the agreement 
of the PIP, defined as a research and development programme aimed at ensuring that the 
necessary data are generated to determine the conditions in which a medicinal product may 
be authorised to treat the paediatric population.  
The PIP details the planned development in terms of efficacy, safety and quality (age-
appropriate formulation) and timelines for children from birth to 18 years. In other words, 
the PIP contains a full proposal of all the studies necessary to support the paediatric use of 
an individual product, intended for diagnosis, prevention or treatment of a condition. 
The paediatric population is in fact composed of a number of population subsets, thus the 
PIP has to specify which population subsets need to be studied, by what means and by 
when.  
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In addition, PIP must describe any measures to adapt the formulation of the medicinal 
product to make its use more acceptable, easier, safer or more effective for the different 
subsets of the paediatric population. 
The introduction of the PIP in the legal framework of medicines has finally ensured, or at 
least is expected to ensure, the availability of paediatric data and results, to cover the needs 
of all age groups of paediatrics, from birth to adolescence. All the regulatory and scientific 
strategy for developing a product is changing and the development of medicinal products 
for potential use in the paediatric population becomes also an integral part of the 
development of medicines for adults.  
The PIP has to be submitted to the Paediatric Committee early during the product 
development before marketing authorisation applications are submitted. Particularly 
applications for a PIP, including a deferral if relevant, and/or for a waiver should be 
submitted no later than the completion of the relevant human pharmacokinetic studies in 
adults, unless justified. This time point was chosen to ensure that the paediatric 
development of the product is considered at a very early stage of the overall product 
development rather than as an afterthought.  
An ad hoc procedure is followed by the PDCO to evaluate and finally agree the PIP. In the 
specific the evaluation of a PIP is conducted over two periods of 60 days each—maximum. 
EMA scientific coordinators and two members of the PDCO contribute to the PIP evaluation 
in a written report (PDCO Summary Report), which is then discussed by the PDCO. In most 
cases, the Paediatric Committee requests modifications of the proposal at the end of the first 
60 days period. The request for modification identifies all necessary changes to study non 
clinical and/or clinical protocols and/or formulations. At this point it is expected a clock 
stop at day 60 to allow companies to respond to requests for modification of the plan 
(approximately 3 months) and once evaluated, PDCO positive or a negative opinions on 
PIPs and waivers are transformed into binding EMA decisions. 
Notably the PIP is legally binding for the pharmaceutical companies willing to seek 
marketing authorisation since the results generated by the agreed PIP are then assessed by 
the Competent Authority granting the marketing authorisation (the Committee for 
Medicinal Products for Human Use for the centralised procedure) or the variations. 
2.4 The Paediatric Committee 
The Paediatric Regulation brings the creation and operation of a new scientific committee of 
experts at the EMA, the Paediatric Committee, set up in July 2007 and primarily responsible 
for reviewing and agreeing applications for paediatric investigation plans including 
deferrals, and/or waivers. 
This committee aims to ensure expertise and competence in paediatric medicines and to 
provide scientific opinions on any development plan for medicines for use in children. 
The PDCO membership includes five members of the Committee on Human Medicinal 
Products (CHMP) plus their alternates. These five members will provide an important link 
between the two committees. Member States, that have no representatives as CHMP 
members in the Paediatric Committee, appoint a member and an alternate. In addition, the 
European Commission appoints three members plus alternates, to represent health 
professionals, and three members plus alternates to represent patient associations, following 
a public call for expressions of interest and after consulting the European Parliament. The 
EMA and the Commission are expected to cooperate to ensure that the final composition of 
the Committee, including members and alternates, covers those scientific areas relevant to 
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paediatric medicines. The members, alternates and experts must not have any financial or 
other interests in the pharmaceutical industry that could affect their impartiality. 
The Paediatric Committee has a number of important responsibilities. Its most important 
task is to assess the content of PIPs ( which may also include requests for waiver and/or 
deferrals) for medicinal products and to release opinions on them. The Committee may itself 
impose a waiver from the requirement to provide data from a PIP, if it considers that the 
product may be unsafe or ineffective in the paediatric population or that the product will 
not provide any significant therapeutic benefit. In fact, when assessing a Paediatric 
Investigation Plan, the Paediatric Committee must consider whether or not any proposed 
studies can be expected to be of significant therapeutic benefit to and/or fulfil a therapeutic 
need of the paediatric population.  
Other specific tasks include establishing an inventory of specific needs for paediatric 
medicinal products (still under preparation) and giving scientific input in the development 
of any documents related to achieving the Regulation’s objectives. The Committee should 
avoid requirements for studies in children causing any delay in the marketing authorisation 
of the medicine for other populations. This is to ensure that medicines are developed for 
children based on the therapeutic needs of children rather than just on the basis of when the 
paediatric market may be profitable or incentives might be financially attractive. The 
Committee also has an advisory role for the EMA and for the European Commission on any 
question relating to the paediatric use of medicines. This includes giving advice on 
communication issues relating to conducting research in the paediatric population, on the 
compliance of an application for marketing authorisation with an agreed PIP or on the 
safety, quality and efficacy of a medicinal product for paediatric use.  
2.5 How to increase paediatric research 
One of the above described objectives of the Paediatric Regulation is to increase paediatric 
research. Clinical trials in the paediatric population require specific expertise, in some cases 
specific methodology and specific facilities, and should be carried out by appropriately trained 
investigators. Thus in order to facilitate this aspect the Paediatric Regulation established the 
creation of an European Network of Paediatric Research and research funding.  
The EMA is responsible for establishing a network of existing networks, centres and 
investigators of paediatric research, which was set up in 2011 and whose objectives are to 
coordinate studies relating to paediatric medicinal products, to build up the necessary 
scientific and administrative competences at European level, avoiding duplication of studies 
and testing in children. The EU network is expected to serve as a tool for industry to 
perform trials with children in keeping with the PIP. Both technical and/or administrative 
competences in the performance of paediatric clinical trials through effective collaboration 
are expected benefits, which will allow to avoid duplication of work and efforts, making the 
use of facilities more efficient and profitable, to develop common methods of working with 
special attention to quality assurance. Facilitation of recruitment of patients and avoiding 
unnecessary studies in children are expected.  
2.6 Transparency and information 
Transparency and information are other key words of the Paediatric Regulation. Through 
increased availability of information, the safe and effective use of medicinal products for 
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children can be increased so promoting public health, preventing the duplication of studies 
in children and avoiding unnecessary studies. One of the measures is making all paediatric 
trials included in the European database (EudraCT) accessible to the public both for protocol 
and results-related information. The increase in paediatric clinical trials transparency 
beginning from the planning and recruiting of patients to the on-going and finalised studies, 
is another target of the Regulation. All decisions of the EMA on PIPs, deferrals or waivers of 
the paediatric development are made public and routinely published on EMA website. 
Moreover where authorisation is granted, the results of all those paediatric studies, any 
waivers or deferral, are included in the Summary of Product Characteristic and, if 
appropriate, in the Patient Leaflet of the medicinal product, whether or not all the paediatric 
indications concerned were approved by the competent authority. 
3. What is changing with the Paediatric Regulation 
The Paediatric Regulation is a remarkable step forward, because for the first time in Europe 
it is a regulation that is provided by law and provides direct economic support for 
paediatric clinical trials and indirect support for pharmaceutical industries. 
Since its establishment in July 2007 the PDCO has assessed a large numbers of procedures: by 
August 2011, 1087 validated PIPs/waivers have been submitted by pharmaceutical companies 
covering nearly 1516 indications., and of which 259 have been requests for a full waiver. 
Of the 1087 validated applications: 
  74% referred to medicinal products not yet authorised in the EU at the time of the entry 
into force of the Regulation (so called “Article 7 applications”). 
 24% referred to products already authorised, still under patent or supplementary 
protection certificate, in view to submitting a variation/extension for a new indication, 
pharmaceutical form or route of administration (so called “Article 8 applications”). 
 4% referred to an off-patent product developed specifically for children with an age-
appropriate formulation (so called “Article 30 applications”). 
In the first year of the implementation of the Regulation, most of the applications were 
“Article 8 applications”. After about a year, the balance changed towards a higher 
proportion of “Article 7 applications”. This change is confirmed in 2010 and 2011. For 
“Article 30 applications”, the number of applications submitted is still very low. 
In 2011, Olski et al. published the first analysis of the general impact of the Paediatric 
Regulation on the development of medicinal products in Europe. Three years after its 
implementation an increase in the availability of medicines with age-appropriate 
information in the next years is shown at least as reported by the high number of PIPs 
despite the still modest number of clinical trials performed (Olski TM et al., 2011; Davies et 
al., 2010; Rocchi et al., 2010). 
Most of the paediatric developments will be performed in therapeutic areas, such as 
endocrinology, oncology, infectious diseases and cardiovascular diseases, which relates to 
the economical importance in the adult market, while other areas such as pain management 
still remains less studied. 
A high number of full waiver requests are reported for more prevalent adult-only 
conditions, such as atherosclerosis.  
On the light of these results and from a qualitative approach, the Paediatric Regulation 
appears to fulfil its core goals. The quality of the plans submitted has improved also due to 
the PDCO demanding better methodological approaches. The PDCO’s intervention has also 
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increased the number of medicines that will be studied in neonates, the most neglected 
subset to date. A high proportion of agreed PIPs require a specific age-appropriate 
formulation, more than originally proposed, and all this should help meet the clinical needs 
of children and health professionals. 
The agreed-upon PIPs will provide important short- and long-term safety data.  
Some paediatric development plans have been also preliminary discussed during scientific 
advice procedure, a free access granted by the Paediatric Regulation for any request 
containing questions on the paediatric development. The advice is provided by the ad hoc 
SAW /Scientific Advice Working Party) of the Committee for Medicinal Products for 
Human Use (CHMP) and is adopted by the CHMP. For the paediatric requests, members of 
the PDCO are routinely involved in the procedure as experts. Notably, since the entry into 
force of the Paediatric Regulation, the number of scientific advice on questions related only 
to paediatric development has increased steadily, with a total of 32 procedures in 2010. A 
high number of so-called “mixed” scientific advice/protocol assistance requests, i.e. 
covering both adult and paediatric development, have also been submitted for which 
members of the PDCO are generally involved. Compared to 2009 where 35 procedures were 
submitted, the figure increased to 48 in 2010 (European Medicines Agency [EMA], 2011, 
thereafter EMA, 2011).  
Indeed, there is still a need for additional paediatric information on off-patent medicines 
and to date, in June, 2011, only a PUMA has been granted for the medicinal product 
Buccolam (midazolam) intended for the treatment of prolonged, acute, convulsive seizures 
in paediatric patients from the age of 3 months to 18 years. The funds for the research of off 
patent drugs granted by the European Commission are currently in stand by and there is 
hope that next calls of the EC Framework programs will take into account the paediatric 
population. 
One thing is for certain, the whole R&D process from pharmaceutical, non –clinical and 
clinical to post-marketing studies is continuously evolving and changing starting from 
quality (need for age appropriate formulation specifically addressed to paediatrics), to non 
clinical (need for studies on juvenile animals to evaluate the toxic potential before any 
administration to paediatrics), clinical (need for non conventional approaches in terms of 
study design and size of the population, choice of adequate endpoints), and post-marketing 
issues (need for ad hoc pharmacovigilance measures).  
In the following sections, a short overview of how R&D process is improving in the light of 
new Paediatric Regulation’s requirements is provided. 
4. Quality: Need for age appropriate formulation specifically addressed to 
paediatrics 
The development of ad hoc formulations intended for the paediatric population is a crucial 
issue and unfortunately, nowadays there is still limited scientific and regulatory experience.  
Regulatory initiatives have been undertaken to provide guidance in developing ad hoc 
medicine. As mentioned above, the adoption of the Paediatric Regulation plus the 
consequent demand for paediatric studies have started to change the context by finally 
strengthening the focus on better formulations for children.  
The current legislation establishes that pharmaceutical companies need to develop a specific 
age-appropriate paediatric formulation together with an adequate packaging, user 
instruction and where relevant dosing device and/or administration device prior to 
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performing clinical studies in the paediatric population. All these pharmaceutical 
development aspects may be fundamentally different to those of the existing adult product.  
This new regulatory environment stimulates the rational development and testing of age-
appropriate medicinal products intended for the paediatric population. Part of this 
legislation (Recital 9, 10 ; Art. 15) requires that applicants for medicinal products for use in 
the paediatric population should submit their plans for the development of such products in 
the form of a PIP for approval, or a waiver, or a deferral. 
The spirit of the legislation was to i) to encourage companies to develop specific, ‘age-
appropriate’ paediatric formulations and ii) to develop relevant and acceptable formulations 
with convenient and precise dosing characteristics, on an industrial scale suitable for 
marketing. (i.e. the spirit is not to place the preparation of paediatric medicines in a context 
which is ad hoc, extemporaneous, or magistral preparations).  
It is now well accepted that children are not simply small adults and their treatment with 
pharmaceutical medicines poses problems which are not seen to the same extent in adults. 
For example, the lower age group subsets of the paediatric population are simply unable to 
swallow conventionally sized tablets; they may be particularly sensitive to certain excipients 
that are otherwise acceptable in adult formulations, or there may be compliance problems 
since they often need to be persuaded to take their medicines, and so on.  
Few European Medicines Agency (EMA) documents have been released with the aim of 
providing guidance on the principles that should be taken into account in the development 
and the assessment of pharmaceutical aspects of medicinal products for paediatric use.  
In the regulatory framework, the starting point was the “Concept paper on the development of 
a quality guideline on pharmaceutical development of medicines for paediatric use” 
(Committee for Medicinal Products for Human use [CHMP] et al., 2008, thereafter CHMP et 
al., 2008) which was the first step to a scientific and harmonised approach to the development 
of a guideline that provides adequate tools for responsible development of a medicinal 
product for use in the different subsets of the paediatric population. Information sharing with 
authorities from other regions (e.g. the FDA) would further support global development.  
This guidance however, was preceded by other guidelines published by the EMA, such as:  
 “Excipients in the Dossier for Application for Marketing Authorization of a Medicinal 
Product” (CHMP, 2007a): a key guideline on the quality of excipients, into effect on 
January 2008.  
 “Excipients in the Label and Package leaflet of Medicinal Products for Human Use” 
(European Commission [EC], 2003, thereafter EC, 2003): one of the most relevant 
guidelines in the context of quality related to safety, even if established safety profiles 
and warning statements are based mostly on data in adults, and apply to the adult 
population. However, it acknowledges that some excipients are not entirely inert but 
may have side effects.  
One of the issues to consider is that the benefits of a medicinal product for paediatric use 
should outweigh the potential risks associated with its use by the different subsets of the 
paediatric population as defined in the “International Conference on Harmonisation (ICH) 
Topic E 11 Note For Guidance On Clinical Investigation Of Medicinal Products in the 
Paediatric Population” (Committee for Proprietary Medicinal Products [CPMP], 2003, 
thereafter CPMP, 2003), namely:  
 Preterm newborn infants. 
 Term newborn infants (0-27 days).  
 Infants and toddlers (1 month to 23 months).  
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 Children (2 – 11 years). 
 Adolescents (12 – 16 or 18 years).  
The pharmaceutical development aspects should be chosen with the care for each subset of 
the paediatric population. This classification does not match pharmacological stages. Often, 
the different subsets (from preterm newborn infants to adolescents) require different 
approaches. As a consequence, there might be a need to develop more than a single 
`formulation` which would be appropriate for all ages. On July 2006, the "Reflection paper 
on formulations of choice for the paediatric patient” (CHMP, 2006) was finalised by the 
EMA with the aim of providing a comprehensive summary of the physiological and 
pharmaceutical issues. These could be taken into account in the development of paediatric 
medicines, looking at the acceptability of different dosage forms, administration volumes, 
size of unit dosage, taste and the acceptability and safety of excipients in relation to the age 
and development status of the child.  
Afterwards, on January 2010 the “Guideline on the investigation of Medicinal Product in the 
Term and Preterm Neonate” (CHMP & Paediatric Committee [PDCO], 2009, thereafter 
CHMP & PDCO, 2009) was effective and specifically addressed to the investigation of 
medicines intended for neonates.  
An additional consolidated guidance on the pharmaceutical aspects of medicinal products 
for paediatric use was anticipated to be finalised before the end of 2009 in the concept paper. 
However, “the Draft of Guideline on Pharmaceutical Development of Medicines for 
Paediatric Use” (CHMP, 2011) has been released for consultation in May 2011. As the 
deadline for comments is December 2011, the guideline will likely to be published in 2012 as 
an outcome of a collaborative work between the CHMP, Safety Working Party (SWP), 
Paediatric Committee, and external experts. This guideline aims to provide additional tools 
for the rationale pharmaceutical development of medicines for children between birth and 
18 years of age.  
4.1 Points to consider in developing an age appropriate formulation  
Paediatric formulations that permit accurate dosing and enhance adherence (i.e., simple 
dosing regimen, better palatability) are required for paediatric clinical pharmacology studies 
and an age-appropriate dosage form must be made available for children.  
The goal should ideally be to develop relevant and acceptable safe formulations, which have 
convenient and precise dosing characteristics for the intended population, made on an 
industrial scale suitable for marketing.  
Basically, the critical points of the paediatric formulations to be considered are related to:  
 Routes of administration.  
 Appropriate dosage forms: taking into account a formulation that the child can take 
(size, volume, taste, ease of administration, dosing regimen).  
 Dosing accuracy (strength, dose criticality, administration device).  
 Treatment duration and setting.  
 Appropriate safety considering administration device, handling, excipients such as 
preservatives, antioxidants, colorants.  
 Acceptable organoleptic properties including taste, after taste, smell, colour, texture.  
 Minimal impact on life style, ease of administration, good acceptability by children and 
parents/carers.  
 Cost-effectiveness. 
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4.2 Development of paediatric formulations for paediatric subsets  
4.2.1 Preterms and neonates  
As above cited, the guidance (CHMP & PDCO, 2009) was released by the EMA and entered 
into force on January 2010 on the investigation of medicinal products in the term and 
preterm neonates. This guideline addresses the considerations, requirements for the design 
and conduct of clinical trials in premature and term neonates. It includes background 
information on the maturation of organs and of body functions. Formulations and route of 
administration are also mentioned.  
Age-appropriate formulations and strengths using appropriate excipients must be 
developed to avoid extemporaneous preparations, even more so for neonates. In neonatal 
practice medication errors are commonly due to use of inappropriate formulations or 
strengths which require complex calculations and measurement of very small volumes or 
multiple dilutions. Special care should be given to extremely low birth weight (birth weight 
<1000 g) and very low birth weight (birth weight <1500 g) newborns.  
Notably, attention must be focused on the excipients which can be used on adults and older 
children, may be toxic in neonates because of their immature and rapidly changing 
metabolic & elimination system (e.g. less predictable absorption, different volume of 
distribution, immature clearance mechanism). The salt of the active ingredient and the 
chemical nature of the preparation must be carefully considered to avoid administration of 
excessive amounts of electrolytes.  
The intravenous (IV) route is normally used in clinically unstable term and preterm 
neonates. The volume of IV infusions (blood products, total parenteral nutrition (TPN), 
other IV medication) contributes critically to daily fluid intake. Therefore careful thought 
must be given to the volume of injection not to exceed the daily fluid allowance. Osmolarity 
of solutions, pH and infusion rates must be carefully considered. A suitable strength of an 
IV formulation with an appropriate solvent should enable to administer appropriate 
volume.  
Oral administration should be used when possible and appropriate in the neonatal 
population. Preparations for oral administration are most likely to be liquid dosage forms, 
keeping the volume to be administered as small as possible. However, as liquid 
preparations more often contains excipients like preservatives and antioxidants, special care 
should be taken regarding the choice of excipients as some may have toxic effects. Sterile 
and/or single use oral dosage forms may be considered in order to avoid the use of 
preservatives and to avoid or to reduce antioxidants. When preservatives are required, the 
concentration should be at the minimum level and a thorough justification for the choice of 
the preservative should be provided.  
Neonates have special needs. If the product is likely to be administered via an enteral (e.g. 
nasogastric, nasojejunal) tube, issues such as viscosity of formulation (to permit flow of the 
product through small tubes [e.g. 6FR/8FR] and avoid blockage), size of particles, 
adsorption to commonly used enteral tubes and interaction with common formula/breast 
milk should be investigated.  
For local or systemic effect a topical administration may be suitable, taking into account skin 
immaturity, especially in preterm neonates, and the large and more permeable and 
moisturised surface area.  
On the contrary, rectal and intramuscular (IM) administration are not commonly used in 
this age group, due to erratic absorption and in case of IM also to painful injections that may 
cause tissue damage. Adverse effects such as muscle contraction and abscess development 
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can be seen after IM administration. In premature neonates, inefficient muscle contractions 
and vasomotor activity may alter pharmacokinetics of the drug. In neonates, decreased 
blood flow may cause variability in drug delivery and absorption.  
4.2.2 Infants  
The rapid maturation, immune system development and total body growth should be 
carefully taken into consideration in developing relevant and acceptable formulations for 
infants. The developmental pattern may occur at a variable level between individuals.  
While the rate of oral absorption is slower in neonates than in older paediatric patients, 
absorption by IM route may be greater by the rich supply of capillaries. In early infancy, the 
low concentration of bile salts may decrease the absorption of lipid-soluble drugs. Above 1 
year of age, infants metabolic activity increases, dose adjustments should be made 
accordingly. Infant skin is mature; their epidermis is hydrated to a greater extent than 
adults. During the first years of childhood, the surface area to body weight ratio in infants 
may be twice that of adults and subject to a change. 
The choice of the excipients should be properly justified in PIP in relation to age, treatment 
duration, severity of disease, rational use, due to infants' juvenile metabolizing capacity. 
Risk-benefit analysis should support proposed excipient selection. Some excipients are not 
entirely inert, therefore may present safety problem. Even the so-called child-friendly 
excipients should be kept to a minimum. When only intended for aesthetic purposes, 
excipient use should be avoided. It would be a better approach to use marking or embossing 
instead of inclusion of colouring agent into formulation composition.  
As a result of lack of cognitive maturity and coordination, infants are similar to neonates in 
terms of being fully dependent on caregivers. Appropriate dose delivery and administration 
devices have to be used. The physiological capability of the infant should be considered. For 
instance, dry powder inhalers are not appropriate for infants as they cannot generate 
sufficient air flow. Pressurized metered dose inhalers may be applied to infants from birth if 
in combination with a specific spacer system and face mask. Administration devices 
providing accurate dose delivery should be considered. Validated droppers are convenient 
for infants. Concomitant administration with TPN using the same IV access is discouraged, 
as TPN formulations are highly variable and may induce oxidation.  
4.2.3 Children  
This period is much more mature compared to newborn and infants. However, children 
constitute a subset of paediatric population, with a distinct age range situated at different 
stages of their physiological and cognitive development. The magnitude of doses varies 
throughout childhood. Hence, major difficulty would be to choose the optimum formulation 
applicable for all age range. In this respect, the points to be considered are as follows; 
younger children are still under psychomotor development, school age children are subject 
to skeletal growth, weight gain and switch from home life to school life, the onset of puberty 
can occur as early as 9 years of age. Therefore, stratification by age within this category may 
be needed for the decision on drug delivery system. Considering the child’s cognitive 
ability, further subdivision of this age group into pre-school children (2-5 years) and school 
children (6-11 years) would be helpful. The formulation strategy should be chosen on a case 
by case depending on the drug’s physicochemical characteristics, dose and patient’s disease 
status and age. Accurate dosing must be ensured with an appropriate packaging and 
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administration device. For instance, if the incorrect dosing risk is high, it would be a sound 
approach to use unit dose, pre-filled oral syringes or cups for the single use . The criticality 
of the dose should be established to determine the choice of the drug delivery system. 
Oral solid unit dosage forms which are intended to be ingested whole may be acceptable for 
older children. The compelling question is at what age children can safely swallow 
conventional tablets and capsules. Anecdotal evidence suggest that with support and 
training, children aged < 6 years can learn to take solid dosage forms but little information 
on acceptable size of tablets/capsules is available. Formulations providing dose flexibility, 
such as liquids and multiparticulates (e.g. sprinkles, minitablets, pellets, granules) can be 
used across different age groups of children. Opening the capsules and mixing with 
food/beverage facilitate the administration to young children. However, this process should 
not cause any inconvenience for the child and parent/caregiver. It must be ensured the 
bioavailability of the formulation would not be affected and handling would not cause any 
harm to parent/caregiver (e.g. exposure to irritating or cytotoxic drugs must be avoided). 
Minitablet is suitable for young children. Orodispersible formulations (e.g. orodispersible 
films and tablets) are encouraging due to their ease of administration, lack of necessity to 
use water and thereby, adaptability to different settings such as developing countries 
depending on the feasibility of pharmaceutical manufacturing. Liquid formulations would 
be alternative if the medication can be administered at an appropriate volume (< 5 ml for 
children under 5 years and < 10 ml for children of 5 years and older). Furthermore, 
formulation should taste pleasant to avoid noncompliance.  
The usability of the device by the paediatric patient is essential. For instance, inhaling 
devices should not be too complicated for the pre-school children or children with lack of 
coordination. Educational training programmes would be helpful to increase adherence to 
inhalers. Children should benefit from advances in drug delivery. Innovative formulations 
such as sipping straw (Clarosip® Straw) and dispensing spoon (comprising preloaded drug 
that on exposure to water turns into a pudding like texture) (Parvulet®) are promising 
approaches facilitating the administration of dose in an appealing way to paediatric patient. 
Nevertheless, still few innovative formulations are for prescription drugs on the market. The 
main limitation of available innovative formulations is the delivery of a single dose. For 
older children who are able to swallow solid oral dosage forms, multiple dose delivery 
approaches exist. For example, the rectangular tablet with multiple fraction bars and deep 
score lines on both sides has been a smart design allowing flexible drug dosing in function 
of the body weight of paediatric HIV patients. Modified release formulations would be an 
easy option to omit administration of doses during school hours.  
The place and pattern of treatment should be taken into account in paediatric formulation 
development. The administration setting affects the selection of dosage form. Application of 
different formulations would be feasible in hospital, while it is not in community. The 
practicality of using different drug delivery systems in different clinical settings, particularly 
in paediatric intensive care setting should be considered. The condition (acute/chronic) and 
severity of the disease plays a role on the selection of appropriate dosage form. During an 
acute illness, the ease of application becomes an critical parameter. Because the child is more 
fractious, uncooperative and the medication is relatively unfamiliar each time it is used. 
Formulation used for a chronic condition may cause repeated cumulative exposure to 
excipients. Therefore, the acceptable daily intake and safety limits of excipients for children 
must be checked.  
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Acceptability on entire age group should be considered. In the matrix given in “Reflection 
paper on formulations of choice for the paediatric patient “(CHMP, 2006), ‘children’ have 
been further divided into pre-school children (2-5 years) and school children (6-11 years) 
because of the significant changes in the ability to handle some dosage forms between 2-12 
years of age. The pre-school period is particularly challenging: neither passive nor active 
compliance, can be expected. Patient should be kept at the forefront of any evaluation. 
Conducting research directly with children across various defined age subsets is necessary 
to gain insight, in particular, to understand acceptability and applicability of different 
dosage forms.  
Palatability is critical to compliance. Many drugs taste bitter or irritate the oral cavity. 
Undesirable taste and aftertaste have to be improved to provide acceptability of the 
formulation . Taste masking may rely on sweeteners but often requires multiple approaches. 
The taste has been started to be seen as a major component of pharmaceutical quality 
aspects. Additionally, texture (grittiness), smell and ease of swallowing need to be 
evaluated. Different types of flavours may be more acceptable in one region than another, 
due to cultural differences.  
Topical administration of drugs is also feasible. However, it should be considered that 
young children have a larger surface area to weight ratio than adults which may result in 
profound systemic effects.  
As alternative promising drug delivery systems, transdermal formulations improve patient 
acceptability, ideally suit to needlephobes, provide controlled delivery to relevant skin 
layers and systemic circulation, reduce dose requirement and bring advantage of ease of 
application and parent drug management. Needle-free drug delivery systems (e.g. 
microneedles) can mitigate against the pain that can be associated with the parenteral route 
of administration.  
4.2.4 Adolescents  
Adolescence period is subject to physical and cognitive changes. The effect of pubertal 
growth spurt and action of hormones are needed to be to considered during formulation 
development for adolescents. The pattern of growth should not be altered by the medicinal 
products.  
Adolescents constitute a challenging age subset, especially in terms of noncompliance, due 
to being in a period of psychological and social transition between childhood and 
adulthood. Although the ability to cope with dosage form increases, adolescents may reject 
to take the medication under the effect of peer pressure, emotional change or as they find 
the medication too childish. As adolescents are responsible of taking their own medication, 
acceptability is vital for their coordination and compliance. The matrix given in “Reflection 
paper on formulations of choice for the paediatric patient” (CHMP, 2006) indicated 
adolescents` dosage form of choice is mainly peroral and topical/transdermal formulations; 
rectal formulations are accepted under reserve. However, this statement does not reflect an 
evidence-based finding. Given the limited experience with acceptability of different dosage 
forms, further comprehensive research should be performed.  
4.3 Conclusive remarks  
Four years have elapsed since the entry into force of the Paediatric Regulation which has 
stimulated the conduct of high-quality research with the increase in paediatric trials. 
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According to "Report to the European Commission on companies and products that have 
benefited from any of the rewards and incentives in the Paediatric Regulation and on the 
companies that have failed to comply with any of the obligations in this Regulation, 
covering the year 2010” (EMA, 2011), the number of companies which have benefited from 
an extension of the Supplementary Protection Certificate in some Member States is 
increasing but this number may still be considered limited. The implementation of the 
paediatric regulation resulted in a large number of PIPs including measures for the 
development of age-appropriate formulations and progress should continue incrementally. 
Developing high quality appropriate formulations for a sensitive population with individual 
needs is a challenging task. Therefore, engagement between key stakeholder including 
companies, regulatory authorities, health professionals and society is needed. Concerted 
effort will pave the way for a PIP with a strongly written quality section and thereby, 
increase the commercial viability of medicines intended for children. Paediatric 
formulations should not be as an add-on to adult formulations; conversely, it should be seen 
as an integrated part of the overall drug development programme, unless a waiver is 
appropriate. The “Guideline on Pharmaceutical Development of Medicines for Paediatric 
Use” (CHMP, 2011) will provide additional tools for the rationale paediatric formulation 
development and highlight the main aspects for justification of strategy. PIP should ensure 
that every study contributes to the paediatric formulation development pathway. Often, 
problems related to formulation are identified late during the paediatric clinical trial and led 
to delays and complications in the conduct of the trial. For early scrutiny of pharmaceutical 
quality-related issues, timely submission and subsequent evaluation of potential 
formulations would facilitate to investigate the intended marketed product in paediatric 
clinical trials and would let PIP amendments related to formulation aspects. Research into 
novel dosage forms and administration devices along with effective utilization of existing 
drug delivery technologies will be pivotal to develop acceptable, safe, feasible and age-
appropriate formulations for children. 
5. Non clinical: The need of studies on juvenile animals in order to evaluate 
the toxic potential before any administration to paediatric population 
The 20th century history of drug research and regulation shows that dramatic tragedies such 
as sulfanilamide (Wax, 1995), thalidomide (Choonara & Rieder, 2002) and TGN 1412 
(Suntharalingam et al., 2006) cases facilitated the passage of stronger laws. The elixir of 
sulfanilamide case can be considered one of the earliest example of disaster in paediatric 
medicine therapy. After its safety use in adults in fact, an elixir of sulfanilamide was 
developed to enable administration to children, using diethylene glycol as the solvent 
because it was odourless, sweet, and syrupy, but without investigate its toxicological 
properties. Since diethylene glycol is highly toxic causing gastrointestinal, metabolic, renal 
and hepatic failure, more than one hundred Americans, many of them children, died and 
this incident was the main cause of passage, in 1938, of the USA federal Food, Drug, and 
Cosmetic Act. 
Other incidents, since then, have induced serious adverse reactions in children (Choonara & 
Rieder, 2002) but in parallel multiplied efforts have been made from Regulatory agencies in 
the world, with the commitment of many organizations, including academy and paediatrics, 
to ensure that paediatric drug therapies are developed with the same level of scientific and 
clinical rigor as adult therapeutic agents. These efforts culminated in USA and Europe (EU) 
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paediatric initiatives. In Europe, the Paediatric Regulation was preceded by the ICH 
Guidance for conducting studies in the paediatric subjects (International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use [ICH], 2000, thereafter ICH, 2000; CPMP, 2001) and it was also accompanied by 
guidance documents on various themes in the same field, including non clinical 
investigation of products in the neonatal population. In November 2008 a specific 
Nonclinical Working Group was created by the PDCO in order to assure consistency of 
paediatric investigational plan (PIP) evaluation (Silva-Lima et al., 2010). In the following 
paragraphs it is specifically discussed the role of juvenile animal studies in developing 
drugs for paediatric use. 
5.1 Regulatory situation 
5.1.1 Legal rules  
The rules governing the clinical development of drugs and their placing on the market are 
described in the EU Regulations and Directives. The first are the most important legal acts 
after the treaties. They create the same rules for all citizens of EU Member States (MS), are 
uniformly valid in all MS of the Community, have direct effect, and should not be 
transposed into national law. Taking into account the lack of adapted children medicine in 
Europe, the European parliament put in place the Paediatric Regulation bringing profound 
changes as described above in the dedicated section of this chapter. 
The Directives are binding legislative acts, directed to MS. They provide the criteria and the 
principles according to which individual MS govern, by means their own acts, matters for 
which harmonization/convergence of disciplines, in different EU countries, are necessary. 
Directives always needed a period in order to be transposed into national law. To simplify 
and harmonize the rules and administrative provisions governing clinical trials in Europe, 
Directive 2001/20/EC (European Parliament and the Council of the European Union, 2001), 
also known as Clinical Trials Directive, was enacted; its scope is wide and includes every 
clinical trial with every medicine on any human subject within any of the 27 MS including 
paediatric investigation. The Clinical Trials Directive is concretized further by Directive 
2005/28/EC (Commission of the European Communities, 2005).  
The Directive requires that researches/investigators and sponsors ensure ethical review, the 
authorization by competent national authorities before enrolling participants, the drug 
manufacture in compliance with Good Manufacturing Practice (GMP), and rigorous 
observance of the Good Clinical Practice (GCP) principles during the conduction of the trial. 
Furthermore, the Directive requires that any changes related to the execution of the clinical 
study, and its final results, be reported to the supervising authorities. The Directive 
recognizes that non-commercial clinical trials conducted by researchers (without the 
participation of the pharmaceutical industry) may be of great benefit to patients. However, 
after May 2004 no intervention research may be initiated without a “sponsor,” defined in the 
Directive as “an individual, company, institution or organization which takes responsibility 
for the initiation, management and/or financing of a clinical trial.” This means that 
investigators who wish to perform clinical trials without commercial backing must 
themselves become the study sponsors. The administrative responsibilities will be exactly 
the same as those of the pharmaceutical industry for commercial trials. There has been much 
commentary on this issue (Editorial, 2003; Meunier & Lacombe, 2003; Clumeck & Katlama, 
2004). The paper of Welzing et al., 2007 discusses the consequences and implications of the 
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2001/20/EC Directive for independent (“no profit”) investigators involved in paediatric 
clinical trials in relation to the first paediatric investigator-initiated trial at the University 
Hospital of Cologne. The authors of the paper agree that the new rule can improve quality 
of clinical trials, but underline that clinicians and academic researchers cannot meet the new 
requirements and obligations without additional financial support. Their conclusion focused 
to the need to develop new concepts for funding to ensure future paediatric independent 
investigations, for example through specific grants from the EU Community or Member 
States. 
5.1.2 Guidelines 
In addition to legally binding legislation regulatory guidelines, concerning scientific and 
technical requirements for develop and register medicine for human use, were released by 
the regulatory authority (EMA, dedicate section of the site), after discussion with industry 
and experts. In the contest of clinical trial authorization and medicinal product registration 
system, the regulatory guideline cannot be substituted by any other guideline issued by 
scientific organizations and societies.  
Two main regulatory EU non clinical documents considers the aim of non-clinical studies to 
support the development of medicinal products to be used in paediatric population:  
1. Non-Clinical Safety Studies For The Conduct Of Human Clinical Trials For 
Pharmaceuticals (CPMP, 2009). 
2. Non-clinical Testing in Juvenile Animals on Human Pharmaceuticals for Pediatric 
Indications (CHMP, 2008).  
A Food and Drug Administration (FDA) guidance on non clinical issue of paediatric 
medicine is also available (FDA, 2006), recognizing the importance of animal data in 
predicting the potential drug toxicity, and those obtained in juvenile animal studies to 
provide information that might not be derived from standard adult toxicology studies or 
from safety data from adult humans. 
The original “Non-Clinical Safety Studies For The Conduct Of Human Clinical Trials For 
Pharmaceuticals” guideline (CPMP, 2009) was approved in 1995, and revised on December 
2009. Several new sections have been introduced, one of them was dedicated to clinical trials 
in paediatric populations: “when paediatric patients are included in clinical trials, safety 
data from previous adult human experience would usually represent the most relevant 
information and should generally be available before initiation of paediatric clinical trials. 
The appropriateness and extent of adult human data should be determined on a case-by-
case basis. Extensive adult experience might not be available before paediatric exposures 
(e.g., for paediatric-specific indications). The conduct of any juvenile animal toxicity studies 
should be considered only when previous animal data and human safety data, including 
effects from other drugs of the same pharmacological class, are judged to be insufficient to 
support paediatric studies”. 
The CHMP guideline (CHMP, 2008) provides advice on investigation of findings that cannot 
be fully assessed in paediatric clinical trials, with reference to specific concerns, possible 
aggravation of expected findings and to establish safety factors. It highlights that drugs can 
have different safety profiles in adults compared to paediatrics and emphasizes that studies 
in juvenile animals should only be performed after careful consideration of available data, 
age of the intended paediatric population, duration of treatment and “cause for concern” 
identified. Additional data to develop a medicine for children can be necessary because 
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additional or different risk due to immature or growing organism can be possible and 
because children may be included earlier in drug development, before more extensive adult 
data available.  
5.2 Difference between adults and children 
We actually know that adverse events in children may not be always predicted from adult 
data, because a child is not a small adult and paediatric population has immature organs 
rapidly developing. The use of an approved adult drug in children only considering the 
pharmacokinetics (PK) may be problematic, because there are many relevant PK differences 
age-related. Amount of metabolism and kinetics detected in children (particularly neonates) 
can vary in significant way to those observed in adults, these differences can cause over or 
under exposure in paediatric population. The CHMP guideline (CHMP, 2008) provides the 
list of the major systems developing in age dependent manner and for which the functional 
differences existing between human neonates/infants and adults should be take into 
account. The guideline also note that the age ranges only apply to general development and 
it is not applicable to all endpoints related to that organ system. This should be taken into 
account in the design the paediatric drug development program and the individual studies 
(CHMP, 2008): 
 Nervous system: Development up to adulthood 
 Reproductive system: Development up to adulthood 
 Pulmonary system: Development up to two years old 
 Immune system: Development up to 12 years old 
 Renal system: Development up to one year of age 
 Skeletal system: Development up to adulthood 
 Organs and/or systems involved in absorption and metabolism of drugs. Development 
of biotransformation enzymes up to adolescence 
The sensitivity and the cross-species comparative postnatal development are among the 
major points to take into consideration using juvenile animals. There are in fact, evidence 
(Baldrick, 2004) that newborn or infant animals can be more (e.g. tetracycline, sodium 
salicylate, morphine, chloramphenicol) or less sensitive (eg metrazol, codeine, ethanol,) to 
drugs than adults. It is well known that potential differences in sensitivity of juvenile 
animals to drug toxicity can be due to the different stage of development that varies 
among species, strains, organ and in some case also in subcomponent of the same organs. 
A range of publications have summarized functional differences in early postnatal life 
among species used in toxicology testing. A number of these papers have arisen out of 
work performed by the Developmental and Reproductive Toxicology Technical 
Committee of the International Life Sciences Institute (ILSI) and Health and 
Environmental Sciences Institute (HESI). Organ systems examined included: central 
nervous, reproductive, pulmonary, renal, skeletal, cardiovascular, and immune systems 
(Baldrick, 2004). A series of articles reviewing the current knowledge on comparative 
postnatal function and physiologic development are discussed (Cappon et al., 2009) 
observing that in general the rat can be considered the appropriate specie, because most 
of the major organ systems maturation that occurs postnatally in humans also occurs 
during the postnatal period in rat. When the rat is not the relevant species mouse, 
minipig, dog and primate should be considered, comparative age categories are available 
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for rats, minipigs, dogs, non human primates and humans based on CNS and 
reproductive development (Gad, 2001; Baldrik, 2004; Beck et al., 2006). However the 
information on developmental stage across various species is not sufficient without 
knowledge of functional state at these age (Baldrick, 2004).  
The comparison between animals and humans generally refers to the age categories 
described in the ICH guideline (ICH, 2000; CPMP, 2001):  
 Preterm newborn infants. 
 Term newborn infants (0 to 27 days). 
 Infants and toddlers (28 days to 23 months). 
 Children (2 to 11 years). 
 Adolescents (12 to 16-18 years). (dependent on region) 
The guideline recognizes that any categorization of the paediatric population is to some 
extent arbitrary, but provides a basis for thinking about non clinical and clinical study 
design in paediatric medicine development, and neonatal population is still an issue.  
An overview of comparative development of main organ systems in man and different 
animal species, as a basis for species selection and protocol design was one of the topic of 
the workshop on juvenile animal testing organized by the EMA in July 2009, involving non-
clinical assessors and experts of the Non-clinical Working Group of the PDCO and of the 
Safety Working Party (SWP) of the Committee for Human Medicinal Product. The 
presentations and the examples discussed during the workshop concerned brain, 
reproductive system, gastrointestinal system, metabolism, skeletal system, lungs, kidneys 
and immune system, pointing out that the maturation of different organs in various species 
is a key factor to be taken into account when designing juvenile animal studies in relation to 
early exposure of children to medicines (Silva-Lima et al., 2010). 
5.3 Non clinical aspects 
Non clinical safety assessment of new medicinal product intended to be administer in adult 
humans is essential to support clinical trials and eventual drug product registration. Once 
the company has identified and manufactured consistently a promising drug candidate the 
next step in development is to provide evidence to the regulatory authority that it is safe for 
the administration to humans. This evidence must be based on a well designed programme 
of appropriate non clinical and clinical studies, as those illustrated in Table 1. Non clinical 
drug development is a complex, regulatory-driven process designed primarily to assess the 
safety and viability of new molecular entities. Non clinical testing is conducted throughout 
all phases of drug development and, when well done, can maximize the chances of success 
in the clinical phases. Although the terms preclinical and nonclinical are used 
interchangeably it should take in mind that only studies necessary before the first 
administration in humans [First in Man (FIM) clinical trial], can be considered preclinical 
unlike other studies conducted during and in parallel to Phase II and III clinical trials (see 
Table 1). Considering their scientific objectives, non-clinical studies should be designed to 
provide information regarding the primary and secondary pharmacodynamic actions, safety 
pharmacology and toxicology of a compound. Regulatory requirements for safety and 
toxicity studies are more stringent than for pharmacology ones and they must be completed 
in compliance with Good Laboratory Practices (GLP) following the guidelines operating at 
the time. 
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Clinical Phase Pre-clinical/Non clinical data (CPMP, 2009) 
Phase I clinical trials conventionally examine the 
tolerability and the pharmacokinetics of new 
drugs; they are often conducted in healthy 
subjects, but may involve patients in studies with 
interventions that are known to be toxic. It 
should be noted that Phase I clinical trials now 
increasingly include persons with specific 
diseases persons for whom all conventional 
therapies have failed (e.g., terminal cancer or 
AIDS). Such studies may be designated as Phase 
I clinical trials where, in fact, they properly 
should be designated as mixed Phase I/II or 
pure Phase II clinical trials 
 Pharmacodynamic  
 Safety pharmacology (CNS; CV; Respiratory) 
 Toxicology studies (Single dose toxicity, 
Repeated dose toxicity) 
 Initial genotoxicity 
 Initial reproductive toxicology 
 Local tolerance 
 Toxic\kinetic and Pharmacokinetic Studies 
Phase II clinical trials primarily examine the 
short-term pharmacological toxicities and, to a 
lesser extent, the efficacy of new drugs; they are 
conducted in populations with specific diseases 
 Completed battery of Genotoxicity  
 Completed battery Reproductive toxicity 
(male/female)  
 Extended repeated dose toxicity with 
toxicokinetic support  
 Extended pharmacokinetic studies 
Phase III clinical trials primarily examine the 
pharmacological efficacy and, to a lesser extent, 
the short-term toxicities of new drugs. Phase III 
and IV clinical trials are designed to increase the 
survival or the quality of life of subjects suffering 
from a specific disease or condition 
 Chronically used drugs: 
 Chronic toxicity (rodent; non-rodent) 
 Carcinogenicity 
 Supplemental studies (special safety concerns, 
as alerted) 
Phase IV clinical trials, also known as post-
marketing surveillance studies, primarily 
examine the long-term efficacy and toxicity of 
already-marketed drugs 
 
Table 1. The clinical phase and the supporting preclinical/non clinical data 
5.3.1 Information available from adult human safety data  
Safety evaluation programs of a new chemical product should normally include two 
relevant species rodent and non rodent, however for biotechnology-derived 
pharmaceuticals in certain justified cases one relevant species may be sufficient (e.g., when 
only one relevant species can be identified or where the biological activity of the 
biopharmaceutical is well understood). Upon completion of non clinical studies necessary to 
perform clinical trials and put a new drug on the market, the following information are 
available. 
 Rodents and non rodents No Observed Effect Level (NOEL) or No Observed Adverse 
Effect Level (NOAEL) in mg/kg/day obtained after repeated dose administration in 
rats aged from 1 to 24 months (if necessary), and in dogs aged >5-6 months of age. 
 Associated drug blood levels and exposition (Cmax and AUC). 
 Pre-weaning exposure is only in utero or via the milk in pre- and postnatal 
reproduction toxicity studies in rats, since toxicokinetic data is not normally available in 
pre-weaning animals. 
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 Genotoxicity and carcinogenicity (if it is the case) potential. 
In Europe these studies are performed taking into account the European Directive on the 
animal welfare. In November 2010, Directive 2010/63/EU (European Parliament and the 
Council of the European Union, 2010), this Directive revises Directive 86/609/EEC on the 
same subject (Council of the European Communities, 1986). Member States have until 
November 2012 to transpose the Directive into their respective national legislation and the 
new Directive will take full effect on 1 January 2013. Moreover to take into account the 3R 
principles (Reduce, Refinement and Replace) they are designed so that the maximum 
information is obtained from the smallest number of animals. While animal tests cannot 
predict all of the reactions a human, at the end of regulatory assessment of all these data 
available, there are sufficient knowledge of the intrinsic toxicological characteristics of a 
given substance and their target organs of toxicity. 
Until the last few years the majority of studies on juvenile animals are essentially the 
repetition of those conducted in the adult, and performed mainly in the environmental 
regulatory setting, particularly to investigated neurotoxicity (Atchison et al., 1982; Benke & 
Murphy, 1975; Brodeur & Dubois, 1963; Cappon et al., 1997; Rice, 1988; Rigdon et al., 1989), 
or to support investigations certain drug classes used in a paediatric population, e.g., 
antibiotic, anti-emetic, and anti-asthma drugs (Baldrick, 2004).  
Since the entry into force of the paediatric European and USA legislations, the interest of the 
regulators and pharmaceutical industry in non clinical juvenile toxicity studies has taken on 
characteristics of priority as also documented by recent publications on the subject (Baldrick, 
2004; Cappon et al., 2009; Bailey & Mariën, 2009; Silva-Lima et al., 2010). To avoid 
production of unnecessary repetitive not interpretable data and to realize robust juvenile 
animal studies when they necessary, represent the main objectives requiring higher 
consideration than in the past.  
Industry conducted recently a survey to establish whether any findings, other than changed 
sensitivity due to pharmaco/toxicokinetics or metabolism differences, have been seen in the 
juvenile animal studies currently performed after specific regulatory requirements, and 
whether the results could not have been predicted from the adult toxicology or found in 
routine adult animal studies. Ten pharmaceutical companies contribute the survey and 
shared their experiences with over 39 juvenile animal studies (29 in rats, nine in dogs and 
one single dermal study in minipigs). “Novel toxicity was only observed in four studies out 
of the 39 compiled, these comprised a single CNS drug in the rat, two anti-infective in the 
rat and one other anti-infective in the dog. In only one of these cases was it felt that the 
results observed were predictable from the pharmacology, and none of the four were 
predictable from the adult data. In all cases however, the novel toxicity was observed using 
routine toxicological techniques and not as a result of any sophisticated or complex design. 
In one case this was a combination of animal observations and histopathology and in the 
remaining three cases the toxicity was observed at histopathology” (Bailey & Mariën, 2009). 
Taking into consideration these data it might seem that we are not on the right track since 
juvenile animals are required by default rather than following a scientific rationale, but 
surely no definitive conclusions can be drawn based on so small database, and we can agree 
with the conclusion of Silva-Lima et al., 2010: ”It is expected that with the increasing 
experience gained in this area by applicants and regulators, the criteria for requiring these 
studies will be further refined. An increased understanding of their ability to identify 
differences in activity between mature and immature systems, and of their predictive value 
for developing human organs will be gained. Research, follow-up discussions, and 
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experience sharing between all stakeholders will be continued and are encouraged in the EU 
regulatory framework”. The increased database of toxicological studies in young/very 
young animals will contribute to better understand the level of predictability of juvenile 
animals for children. Currently there are examples of products, such as verapamil, 
phenobarbital and theophylline for which juvenile animal data help to predict age related 
toxicity in children (Baldrick, 2004). 
In general, according both to CHMP (CHMP, 2008) and the CPMP guidelines (CPMP, 2009), 
the paediatric patients can be included in clinical trials when adequate pharmacokinetic, 
pharmacodynamic, clinical efficacy and safety data are available in human adults, this also 
implies, in most cases, the availability of a standard non-clinical data package. All available 
adult non clinical and clinical data must be reviewed and considered and their 
appropriateness and extent data should be determined on a case-by-case basis. These 
guidelines suggest that: results from repeated dose toxicity studies of appropriate duration 
(see also table 1 of CPMP, 2009), the core safety pharmacology package, the standard battery 
of genotoxicity tests, and relevant parts of the reproductive toxicity test program and also 
juvenile animal toxicity studies if necessary, should be available and reviewed before 
starting trials in paediatric population. Pharmaco- and toxico-kinetic assessment may be 
exceptionally useful to characterize juvenile toxicity studies since paediatric populations 
metabolize and respond to many substances in a very different manner than adults with 
mature. The data package should be justified, based on the characteristics of the clinical 
study and the intended paediatric population including age group(s), and the need for 
juvenile animal studies should be particularly taken into consideration in case of 
investigation of neonates (0-3 months) and when extensive adult experience might not be 
available before paediatric exposures (e.g., for paediatric-specific indications).  
If previous animal work and clinical safety data are considered to be insufficient for a 
thorough safety assessment in the intended paediatric age group of interest, the juvenile 
studies should be run prior to the conduction of paediatric clinical trials. The need for pre-
clinical juvenile toxicity testing may differ depending on the intended duration of exposure 
in the paediatric population. Consideration should also be given to whether pre-clinical 
and/or clinical studies have identified target organs vulnerable to toxicity, and whether 
these organ systems will be undergoing rapid development while patients are being 
exposed to a given drug. The children and adolescents could have higher recuperative 
capacities than adults, so it important to consider in the study design a period of recovery 
treatment-free assess the potential and timing of reversibility of any adverse effects seen. 
Assuming the need for juvenile study, the key elements described in the EU guideline 
(study design, age and duration, route of administration/doses, selection of species, 
pharmaco-kinetics/toxicokinetics) should be taken into account. 
The analysis of published PIP decisions covering a period from August 2007 up to March 
2009, revealed that, in most cases, the preferred species for juvenile animal studies was the 
rat; in a minority of cases, two species were required, the age animal used at the start of the 
study reflect the age of target paediatric population and generally, the principles stated in 
the guideline were followed (Silva-Lima et al., 2010). The same paper illustrates 4 case 
studies discussed at the EMA workshop related to a new molecular entity with a well 
known mode of action, an oncological new product intended to be administered to patients 
of all ages, a growth factor as a replacement therapy in premature newborns born after 28 
weeks of gestation and a monoclonal antibody for a chronic non tumoral pathology 
emerging around 5 years of age.  
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5.3.2 Targeted approach 
A targeted approach for juvenile animal study design may be used to specifically address 
identified toxicity concerns, and “ primary factors to consider when designing a targeted 
juvenile animal study are: (1) ensure that the organ system of concern is undergoing 
similar developmental processes during the postnatal period as in the intended paediatric 
population; (2) define the age of exposure in the experimental species to ensure that the 
organ systems of concern are at the same stage of development in the animal species as in 
the intended human paediatric population; and (3) ensure that the appropriate endpoints 
are included to enable an in-depth investigation of the organ system of concern” (Cappon 
et al., 2009) The same authors illustrate two examples, based on real paediatric drug 
development programs and accepted by regulatory agencies to support those products, of 
targeted study, one for central nervous system and reproductive development and the 
other focused on liver and reproductive development. This approach support the chance 
to use specific case by case study design to perform suitable, interpretable and not 
repetitive non clinical studies in juvenile animals to support risk assessment for paediatric 
population.  
5.3.3 Pre- and post-natal reproduction studies 
The CHMP guideline the need for nonclinical testing in juvenile animals on human 
pharmaceuticals for paediatric indications (CHMP, 2008) supports the use of the modified 
pre- and postnatal development studies. It states in fact that before performing a juvenile 
animal toxicity study, it should be considered whether a developmental toxicity issue could 
be addressed in a modified pre- and postnatal development study in rats. Key factors that 
need to be examined include, but are not restricted to 
 the amount of the active substance and/or relevant metabolites excreted via the milk; 
 the resulting plasma exposure of the pups; 
 which organs under development that will be exposed during the pre-weaning period; 
 physical development and histopathology investigations.  
The number of animals should be sufficient to draw scientifically sound conclusions, but a 
higher number of animals than necessary should be avoided. When a pre- and postnatal 
study is also being used to address a specific aspect of juvenile toxicity, such a study should 
be extended to include appropriate developmental endpoints: if specific developmental 
endpoints cannot be assessed within the context of pre- and postnatal studies, additional 
juvenile animal studies will be required. In the combined pre- and postnatal development 
toxicity study design (De Schaepdrijver & Bailey, 2009, Cappon et al., 2009) the maternal 
animal is dosed from implantation through post natal dose day 5. Dosing is then suspended 
for maternal animals and the offsprings are directly dosed until maturity ( about 9 weeks). A 
clear advantage of this study is the reduced number of animals to be used, but it is not 
always suitable to investigated potentially additional end points related to target organs of 
concern, and excessive toxicity in the directly dosed pups can be observed (Cappon et., 2009, 
De Schaepdrijver et al., 2008, De Schaepdrijver & Bailey, 2009).  
The guideline CHMP/SWP/169215/2005 is not rigid about the timing for performing 
juvenile animal studies, if these studies are considered necessary, they should preferably be 
available before the starting of clinical studies in paediatric populations, and 
pharmacokinetic data from humans and animals (including juvenile animals if available) 
should also be evaluated before the proposed paediatric clinical trial(s). More flexibility can 
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be considered for paediatric short-term investigations (PK or taste study) in which few 
doses are administered. 
5.4 Conclusions 
The needed and the efforts to develop and register medicine for paediatric population with 
the same level of scientific and clinical rigor as adult therapeutic products have advanced 
over the years through the actual legislation initiatives involving United States of 
America/FDA and EU Community and EMA. In the last five years many experience have 
been gained both by regulators and companies to assess the overall impact of non clinical 
juvenile studies on paediatric human pharmaceuticals risk assessment. The application of 
recent legislations have resulted in a significant increase in the number of juvenile animal 
studies request, in same case they were a simply repetition of the adult design in younger 
animals, but there are cases in which designs are being modified, and targeted designs were 
used, as we continue to gain knowledge from the submitted studies. Particularly important 
is to carefully consider the suitable age and the corresponding developmental stage of the 
children involved in the clinical trial in comparison to the development of the animals 
involved in the non clinical test if necessary. Children in the different interval of age 
considered by the ICH guideline (ICH, 2000; CPMP, 2001) can answer in different way to the 
same product, and neonatal population is still the main issue. As for standard adult non 
clinical study the benefit of harmonized design in juvenile studies should be recognized, 
harmonized study designs, enabling information-sharing across studies through 
standardized approaches to data collection and interpretation, are needed to optimize the 
information from these juvenile studies 
At present there is general agreement that juvenile animal studies can be useful for safety 
determinations, especially when a problem is suspected, they are not prohibitively 
challenging to conduct, available data does not indicate that juvenile animal studies need to 
be conducted routinely to support clinical trials in paediatric patients, but might be needed 
under some circumstances and they should be designed on a case-by-case basis. Currently 
the data base of juvenile animals to investigate paediatric pharmaceutical product is still 
limited, however, and this conclusion might change as more studies are submitted and 
regulators and industry gain more experience with this issue. 
6. Clinical: The need for adequate clinical trials methodologies 
The benchmark for the assessment of the effect of any therapeutic intervention is the 
randomised clinical trial (RCT), its main assets being randomisation, to avoid bias in the 
allocation of subjects to treatments, blindness, to avoid bias in the evaluation of compared 
treatments, and the a priori choice of acceptable error margins, specifically type I and type II 
errors (Baiardi et al., 2011). However, the conduct of clinical trials in children causes several 
methodological, ethical and economic issues limiting paediatric research: small sample sizes, 
children exposure to the potential risks of a trial, and restricted paediatric medicines market 
are just the main examples. 
Notwithstanding these multiple difficulties, understanding the effects of medicinal products in 
paediatric patients is an important goal that is shared by companies, regulatory authorities, 
health professionals and society as a whole (ICH, 2000; CPMP, 2001), and should be achieved 
without compromising the well-being of paediatric patients participating in clinical studies.  
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Traditional drug development approaches do not satisfy the requirements of research in the 
paediatric population. New approaches should be used to address the various practical, 
scientific and ethical issues that arise in paediatric research, as stated by a number of 
worldwide scientific and regulatory initiatives with particular reference, in Europe, to the 
Paediatric Regulation (European Parliament and the Council of the European Union, 2006). 
Methods for extrapolation of efficacy and safety data from adults to children, modelling and 
simulation, adoption of innovative study design and statistics have demonstrated to be the 
more suitable to produce real advancement in this field. 
6.1 Status of the knowledge (What has been done) 
6.1.1 Extrapolation 
The difficulties in performing paediatric trials obliges physicians to extrapolate data from 
the adult to the paediatric population, the first approach usually employed to avoid useless 
studies in children, provided its limitations are properly defined.  
Direct extrapolation can be made on the basis of previous clinical experience and scientific 
knowledge that allow to assume that the disease is the same in children and in adults, and 
that children have reached full maturity in those pharmacokinetic mechanisms involved in 
drug disposition and in the involved pharmacodynamic systems. In such cases, the 
relationship between the two populations is linear and allometric methods based on body 
weight or body surface area can be used to calculate the proportional dose in children 
(Bellanti & Della Pasqua, 2011). 
To be able to use this type of approach, paediatric PK/PD data should be known and they 
should demonstrate a similar exposure/concentration curve as in the adult population. 
However, particularly in neonates and infants, the use of the allometric approach may fail to 
identify the appropriate dosing range (Bouzom & Walther, 2008; Johnson, 2005), thus 
reducing the access to a feasible extrapolation exercise. 
Much more has to be done to facilitate the extrapolation approach also in younger children, 
and in particular to collect data on similar disease course and outcome, and similar primary 
endpoints for efficacy in adults and children. A decision-tree, similar to the one developed by 
the US Food and Drug Administration (Fig. 1), may be of help and is currently under 
evaluation by the EMA Paediatric Committee, that has also created a specific ‘Extrapolation 
Group’. 
6.1.2 Modelling and simulation 
As extrapolation can have limited applicability in children, modelling and simulation (M&S) 
may play a pivotal role in reducing the needs of specific additional paediatric trials. 
Clinical trial simulation (CTS) can be used to assess the impact of a range of design 
characteristics on the statistical power of a clinical trial, and thus to detect a treatment effect 
prior to exposing patients to an experimental drug (Bellanti & Della Pasqua, 2011). CTS 
investigates “what if” scenarios across a different range of conditions or design features (e.g. 
population size, stratification levels, dose range, sampling scheme, and even different 
endpoints) relying on the availability of accurate model parameters and corresponding 
distributions (Bellanti & Della Pasqua, 2011). The possibility to predict ‘trial performance’, 
and thus identify potential limitations in study and protocol design prior to its 
implementation, is one of the main advantages of such a virtual or statistical experiment 
(Bellanti & Della Pasqua, 2011; Manolis & Pons, 2009; Laer et al., 2009; Girard, 2005; Onar et 
al., 2009).  
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Fig. 1. Paediatric drug development decision tree for types of PK-PD studies required in 
children (Johnson, 2005) 
CTS generally employs two types of models: first a drug–action (PKPD) model, which 
comprises pharmacokinetic and pharmacodynamic factors, and then a trial execution model, 
that simulates other important aspects of the trial (e.g. dropout, compliance and protocol 
deviations) (Bellanti & Della Pasqua, 2011; Santen et al., 2009).  
6.1.2.1 PKPD model 
PKPD models incorporate physiological differences between adults and children and 
between different age groups to evaluate variation in pharmacokinetics. This approach may 
allow conversion of the exploratory nature of first-in children studies into a confirmatory 
step (Johnson, 2005). 
When applying bridging techniques, however, it is necessary to clearly understand the 
disease in question and therefore, both disease and disease progression models must be 
taken into account during the comparison of drug response and kinetics in adults and 
children (Manolis & Pons, 2009).  
Disease models can also be applied to simulate treatment response; in fact, when disease 
models are combined with drug models, it is possible to explore the implications of different 
algorithms for dose adjustment (Manolis & Pons, 2009). It must be highlighted, however, 
that the application of sophisticated statistical methods, not achievable by standard linear 
regression techniques, are necessary to use disease models in the evaluation of drug–disease 
interactions and of the role of covariates in pharmacokinetics, pharmacodynamics and 
treatment outcome demands (Bellanti & Della Pasqua, 2011). 
Bayesian statistical concepts are usually the basis on which these methods rely and they also 
include parameterisation based on hierarchical, non-linear mixed effects models that are 
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also known as population approaches, particularly suitable when information on individual 
subjects is limited (a common situation in pharmacokinetic and pharmacodynamic studies 
in children ) as they use the population rather than the individual as the object of the 
investigation.  
Population pharmacokinetic (pop PK) and population pharmacokinetic-pharmacodynamic 
(pop PKPD) models rely conceptually on pooled data across treatment cohorts or even 
across different studies (Anderson et al., 2006) and include the representation of three main 
components:  
 a structural model that describes pharmacokinetics or pharmacodynamic characteristics;  
 a statistical model describing between-subject variability; and  
 an error model that accounts for the residual variability (Bellanti & Della Pasqua, 2011). 
There are different advantages in using these types of approaches: it is possible to assess 
different clinical scenarios without exposing children to any risk, to explore drug, disease or 
covariate effects in a larger number of virtual patients compared to those enrolled in a real 
trial, and to assess the clinical relevance of covariates to drug exposure and to evaluate their 
effect on the treatment response (Anderson et al., 2006; Chatelut, 2008; Yim et al. 2005; 
Knibbe et al., 2002).  
Moreover, the K-PD models, a specific group of nonlinear mixed effect approaches 
introduced into paediatric research, have been developed to describe exposure–effect 
relationships in the absence of drug concentration measurements (Manolis & Pons, 2009; 
Tod, 2008). These models are very useful if the rate-limiting step in drug disposition is the 
drug elimination from the biophase (Bellanti & Della Pasqua, 2011). On the other hand, data 
extrapolation across different scenarios (e.g. different doses, or populations) are not possible 
since no observations are available (Manolis & Pons, 2009). 
6.1.2.2 Trial execution model 
Trial execution models simulate some important aspects of the trial, such as dropout, 
compliance and protocol deviations (Gobburu & Lesko, 2009) and it is therefore possible to 
determine all possible outcomes under candidate trial designs, allowing such trial designs to 
be compared in a strictly quantitative manner.  
6.1.3 Innovative designs 
Many innovative designs have been described up to now, each design having intrinsic 
features that meet the requirements of the paediatric population even if there is no unique 
rule of thumb for choosing a specific approach (Baiardi et al., 2011). 
6.1.3.1 Sequential design 
This study design uses an a priori non fixed sample size and generally needs fewer patients 
compared to a fixed sample size design to reach a conclusion, thus guaranteeing some 
ethical advantages. It also ensures the possibility to stop the trial at any time during its 
course as soon as the scientific evidence of a superiority of one treatment against the other is 
proven (van der Lee et al., 2010). This approach has been developed in the 1960s, but not 
widely used in clinical trials: a review carried out by Goodman in 2009 showed that from 
1963 to 2005, only 24 trials have been performed in the neonatal intensive care setting using 
the sequential design methodology, saving an average of 35% of the enrolled subjects when 
compared to a fixed sample size approach (Goodman, 2009). It is not usable to evaluate 
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survival but it could be useful to evaluate short treatments through surrogate endpoints 
(Baiardi et al., 2011). 
6.1.3.2 Adaptive design 
This approach allows modifications of the trial (e.g. sample size re-estimation, early 
stopping and adaptive randomization ) to be made after its initiation and without 
invalidating the validity and integrity of the trial itself. Reports show that it has been used 
for dose-finding studies, for phase III trials and for phase IV trials in which the method 
allows the saving of up to a half of the subjects required by the traditional design (Chow & 
Chang, 2008). Adaptive designs are very attractive due to their flexibility and can be useful 
especially in early clinical development.  
6.1.3.3 Bayesian design 
The Bayesian design is the data dependent design par excellence (Schoenfeld et al., 2009).  
Data from past studies are here used to form an a priori probability distribution for 
treatment effect, and then merged with the data of the current trial with the aim to provide 
an a posteriori distribution on which conclusions may be drawn (Baiardi et al., 2011).  
This approach is particularly suitable for the paediatric population, since adult data can be 
used in designing the paediatric trial by taking advantage of past information for the sample 
size calculation or by directly including them into the study to generate the distribution 
(Goodman & Sladky, 2005). 
6.1.3.4 Randomized withdrawal design 
This type of design offers two main advantages to the paediatric population: first, patients 
have the opportunity to experience the potential benefits of the active treatment (Della 
Pasqua et al., 2007), and second, the individual receives the placebo for the minimum time 
possible. As a result, a better patient accrual may be achieved and moreover, testing the 
experimental drug against placebo on the responders increases the power of the comparison 
and requires a smaller sample size to achieve the same power of results (Baiardi et al., 2011).  
This design has been recognised as the most appropriate for developing new treatments for 
juvenile idiopathic arthritis at the Paediatric Rheumatology Expert Meeting held in London 
in December 2009. 
6.1.3.5 Randomized Placebo-Phase Design 
The Randomized Placebo-Phase Design (RPPD) approach sets its innovation on the fact that 
the duration of the placebo trial is the shortest possible (Feldman et al., 2001). In fact, it is 
assumed that if the trial drug is active, the earlier it begins, the higher the probability to 
observe a response in short times, and therefore, in this type of study subjects receive 
placebo at different times. In more details, subjects are randomised to placebo for periods of 
different duration. At the end of those periods, all subjects receive the active treatment until 
it is possible to observe a response (Baiardi et al., 2011).  
By guaranteeing the presence of a control group according to an intra-patient scheme, the 
blindness, and the randomisation, the RPPD trial can be classified as a RCT. 
6.1.3.6 Three–stage clinical trial design 
The methodological approach of the three-stage trial design combines the classical RCT and 
the randomised withdrawal trial with the aim to obtain the maximum level of information 
available from each subject. 
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During the first stage, subjects are randomised according to a traditional RCT. At the end of 
this first phase, patients responding to placebo or not responding to the trial treatment are 
then withdrawn from the study, while responders to the active treatment are assigned to the 
second phase of the trial, and non-responders to placebo are allocated to the third (Baiardi et 
al., 2011). Second phase subjects are then randomised again, while patients assigned to the 
third stage enter the following randomised withdrawal scheme: only those who respond to 
the drug in this phase continue the study and are again randomised to take either placebo or 
the active treatment (Honkanen et al., 2001).  
Examples where the study may be potentially useful are in chronic conditions (for which it 
is expected to return to initial conditions when the active treatment is suspended), when the 
therapeutic efficacy in sub-populations has to be determined, in those cases in which 
efficacy in the general population has already been proved, or at the initial stages of the 
drug development when it is necessary to find dosages in small patients cohorts (Baiardi et 
al., 2011; Honkanen et al. 2001). 
6.2 Research aim and results (What have we done) 
Despite the potential of innovative research methods in collecting data on drug effects in 
children and/or developing clinical trials, it seems that their benefits as tools in 
pharmaceutical R&D has remained undervalued and sometimes ignored by key 
stakeholders (Cella et al., 2010; Abernethy & Burckart,2010). This attitude appears to 
contradict those ethical and scientific beliefs that emphasize the need for evaluation of the 
risk–benefit ratio in special populations, such as the paediatric one. 
The Task-force in Europe for Drug Development for Young – TEDDY (Ceci et al., 2009) has 
performed analyses and surveys aimed at collecting data from published literature and 
registrative documents (i.e. EPARs†1) to evaluate the status of paediatric clinical trials 
performed for drugs to be used in children (Baiardi et al, 2009), to explore the current status, 
limitations and perspectives of pharmacogenomic and pharmacogenetic paediatric clinical 
research (Krekels et al., 2009), and to at analysing the quality of the clinical trials for rare 
diseases. 
Results showed that in the period 1995-2005, 60 drugs were licensed for use in children under 
the EMA centralised procedure with a total of 188 paediatric clinical trials included in their 
MA dossiers, mostly concerning diseases predominantly or exclusively affecting paediatric 
patients and serious or life-threatening diseases, occurring in both adults and paediatric 
patients, for which there are currently no or limited therapeutic options. PK studies are 
performed for almost 70% of drugs when they are intended for these diseases. Efficacy and 
safety studies are carried out for more than 90% in drugs intended for diseases affecting 
children only and for more than 75% in drugs for life-threatening diseases (Baiardi et al., 2009). 
Moreover, with reference to pharmacogenomic and pharmacogenetic research in the 
paediatric population, a rather equal distribution of activities across the different research 
categories throughout the world was found. More than 50% of the research activities are 
related to predisposition, i.e. exploratory studies aimed establishing the connection between 
a given genetic trait and the risk associated with a pathology or disease (Krekels et al., 2009). 
                                                 
1†The EPAR is the European public assessment report, a document provides a summary of the grounds 
for a EMA Committee opinion in favour of granting or refusing a marketing authorisation for a specific 
medicinal product. 
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Finally, the analysis of the clinical trials performed and published for 28 orphan medicinal 
products (OMP) approved by the EMA showed that even though all of these drugs can be 
used in children, paediatric studies were performed only in 17 out of the 28 medicines. The 
methodological quality of OMP dossiers is often criticised because of the several limitations 
identified in these dossiers: lack of controlled studies, of active comparator where available, 
of multicentre phase III trials with a suitable number of patients (particularly for diseases 
with a frequency from 5/100 000 to 5/10 000), insufficient exposure to the treatment, use of 
surrogate endpoints or weak proof of clinical benefit (Joppi et al., 2006). TEDDY research 
results, considering the number of clinical trials performed after the authorisation and the 
information still awaited for many of the drugs already authorised, confirm concerns raised 
on the quality of the OMP dossiers (unpublished material).  
6.3 Ethical aspects in paediatric clinical trials 
The main international reference for paediatric research is the ICH Topic E11 guideline 
‘Clinical Investigation of Medicinal Products in the Pediatric Population’ (ICH, 2000) and was 
recognised by the European Union with the ‘Note for guidance on clinical investigation of 
medicinal products in the paediatric population’ (CPMP, 2001). The ICH guideline represents 
the methodological standard to perform scientifically correct and ethically sound paediatric 
clinical trials. In fact, on the basis of the assumptions that the paediatric population has the 
right to use medicines that have been appropriately evaluated and tested, and that it 
represents a vulnerable subgroup, the guideline introduces special measures to protect the 
rights of paediatric study participants and to shield them from undue risk.  
The rights and well-being of children participating in clinical research in Europe have been 
for the first time assured by the provisions of the EU Directive 2001/20/EC (European 
Parliament and the Council of the European Union, 2001) that includes a specific article, 
Article 4, devoted to the protection of ‘minors’ and to the guarantee of their emotional, 
physiological and psychological specificities. This article establishes the condition for the 
start of a clinical trial involving minors, but does not include references to some relevant 
documents such as the Convention of Human Rights and Biomedicine (better known as 
Oviedo Convention) (Council of Europe, 1997) and its Additional protocol on Biomedical 
Research (Council of Europe, 2005), and ICH guideline (ICH, 2000; CPMP, 2001). 
The entry into force of the Paediatric Regulation (European Parliament and the Council of 
the European Union, 2006a, 2006b), that is expected to increase the number of clinical trials 
carried out in the paediatric population, has highlighted the limits of the existing clinical 
trials legislation in particular with reference to children data protection, direct involvement 
into the ‘consensus process’ and respect of the children will during the entire clinical 
research (Altavilla et al, 2008).  
In February 2008, the European Commission released updated recommendations on ethical 
aspects of clinical trials involving children (European Commission’s Directorate-General for 
Health and Consumers, 2008) to tackle the weakness of the existing rules. This document 
provides a new regulatory context integrating principles contained in other various 
international ethical/legal source with the aim of ensuring the protection of subjects 
involved in biomedical research, while recognising the importance of benefits derived from 
research. The Recommendations also clarify the process of assessment of the benefit and risk 
balance, the processes of information and consent/assent according to age groups and level 
of minors’ maturity, the process of ethical review of paediatric protocols, individual data 
protection and insurance issues. In particular, the Recommendations state that: 
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- the child should participate in the decision-making process together with the parents, 
according to his/her emerging maturity;  
- information should be given by an experienced investigator, or his/her adequately 
trained delegate, to each parent/legal representative and to the child in language and 
wording appropriate to his/her age, psychological and intellectual maturity; 
- minors should provide their assent. However, the minor’s assent is not sufficient to 
allow participation in the research unless it is supplemented by the legal 
representative’s informed consent; 
- separate information sheets for adults and children, and separate consent and assent 
forms should be used. The child should be informed of the possibility to freely 
withdraw from the trial, at any time and for any reason, without any disadvantage or 
prejudice especially regarding medical care. 
All of the above mentioned ‘set of rules’ valuable for protecting children during trials have 
represented a real advancement to assure a superior ethical context for children involved in a 
clinical trials. Nevertheless, some important surveys and enquires (Altavilla et al, 2008, 2011; 
European Forum for Good Clinical Practice (EFGCP) Ethics Working Party, 2010) demonstrate 
that the implementation of such provisions, and in particular of EU Directive 2001/20/EC 
(European Parliament and the Council of the European Union, 2001), suffered the lack of 
binding rules and EU guided coordination activities that led to great differences in children 
protection levels in different Member States. Such disparities are particularly relevant when 
related to consent/assent procedures, to the respect of the children’s will, and to other 
fundamental rights (e.g., confidentiality and information). A variable lack of educational 
initiatives and debates involving local and national ethics committee members on the 
Paediatric Regulation and the European Ethical Recommendation (European Commission’s 
Directorate-General for Health and Consumers, 2008) were also reported (Altavilla et al, 2011).  
This situation claims for new initiatives devoted to implement the existing rules and to 
identify better ways for the transposition of legislative provisions. To accomplish this and 
considering the increasing number of paediatric trials in Europe, all the main interested 
stakeholders (e.g., sponsors, investigators, ethics committees, regulatory bodies, patient 
associations) should be requested to take part in the efforts. 
6.4 Future research 
As stated by the Paediatric Regulation, since adults data could only partially be translated to 
children, drugs for children should be studied according to specific plans and 
methodologies; in addition, special attention should be devoted to assuring that paediatric 
studies are conducted under the highest methodological and ethical standards.  
In a field where most clinical trials utilise a conservative design, the application of 
innovative methodologies offers a unique opportunity to develop medicinal products 
tailored to children. Power calculations can be improved by using clinical trial simulation, 
an approach that takes into account a multitude of factors. 
7. Pharmacogenomics (pgx): The need of pgx tools in the light of the 
paediatric regulation 
Pharmacogenomics is the investigation of variations in DNA and RNA characteristics in 
relation to drug response; a subset of PGx, pharmacogenetics studies the influence of 
variations in DNA sequence on drug response (Leeder, 2003). While the traditional 
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approach to diagnosis and treatment has been based around phenotypic definitions of 
disease and the identification of broad groups of patients with similar symptoms to be 
included in ’standardised clinical trials’, the pharmacogenomics approach is based on the 
identification of specific genetic/genomics characteristics and aims at identifying "the right 
treatment for the right patient at the right time", the so called ‘personalised medicine’.  
Of particular interest is the fact that these ‘-omics’ terms have been formulated to define 
approaches capable of identifying groups of biomarkers to be proposed for multiple 
purposes, such as a) to enable the detection of states of disease, b) to stratify patients based 
on biochemical profiles and to monitor disease progression and, in the specific field of 
medicines, and c) to orient the choice of therapy, identifying responders and predicting 
toxicity, paving the way to a customized therapy.  
The increasing introduction of translational approaches in drug development using 
biomarkers and better defined cohorts, has the potential to increase the manageability, 
efficacy and safety of clinical trials while in the longer term possibly reducing their size, 
duration and cost.  
7.1 Omics tools identification and methodological approaches  
Common methodological approaches that can be applied to pharmacogenetics and 
pharmacogenomics studies are described below. 
7.1.1 Case-control association study 
The case-control association study is the study design generally used to assess 
pharmacogenetic effects. This approach examines the active treatment arm of a clinical trial 
and divides subjects into two groups: those with positive response and those with negative 
or no response. The groups are then genotyped for a particular candidate gene considered to 
be related to the treatment phenotype (Russo et al., 2011).  
These types of studies are easy to perform, but they also present a number of potential biases 
or difficulties in interpretation. It is therefore necessary to ensure a good match between the 
genetic background of cases and controls to avoid biased sampling; techniques that can be 
employed to detect or eliminate the potential bias of population stratification are the match of 
cases and controls for ethnicity or the use of multiple unlinked markers (Pritchard & 
Rosenberg, 1999). Moreover, it is also indispensable to consider additional aspects such as 
sample size (Campbell et al., 1995), replication selection of candidate gene polymorphism 
(bioinformatic tools), observation bias (phenotyping and genotyping methods), linkage 
disequilibrium, allele or genotyped analysis, multivariate analysis, gene-gene and gene-
environment interaction, and correction for multiple comparisons to guarantee the quality of 
the study and preventing false positive associations (Russo et al., 2011). 
Efficient and powerful tools to identify inherited DNA sequence variations that contribute 
to phenotypic expression and variability are available to geneticists thanks to very high 
throughput DNA analysis technologies (e.g., single nucleotide polymorphism [SNP] array) and 
databases (HapMap project) harboring information about the genomic positions of DNA 
sequence variations. In fact, it is now possible to test a great amount of polymorphic 
markers for association with a particular phenotype in a single study, the genome-wide 
association study (GWAS).  
GWASs are an important approach for revealing polymorphisms accounting for individual 
differences in drug efficacy and drug safety (Gurwitz & McLeod, 2009), as shown by 
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Crowley et al. and by the NHGRI GWAS catalog that summarized the results of 12 
published pharmacogenomics GWASs (Crowley et al., 2009; National Human Genome 
Research Institute, n.d.) and showed that 6 of these GWASs evaluated the association of 
genetic variation with drug efficacy, five assessed adverse effects, and one examined a dose-
response relationship (Russo et al., 2011). Despite their efficiency and potential for leading to 
useful clinical medicine and public health applications, however, genome-wide association 
studies have been used in only two drug clinical trials so far, each nonetheless providing 
relevant insights for future research (Russo et al., 2011, Maitland et al., 2007).  
A new and promising field of research is pharmacogenomics of miRNA (Lagos-Quintana et al., 
2001; Lau et al., 2001; Lee & Ambros, 2001), defined as the study of microRNAs and 
polymorphisms affecting miRNA function with the aim to predict drug behaviour and 
improve drug efficiency (Mishra et al., 2008; Mishra & Bertino, 2009). MiRNAs, small, 
single-stranded, 21-23 nucleotide-long, independent functional units of noncoding RNA, are 
drug targets that regulate expression of several important proteins in the cell and are 
differentially expressed in malignant versus normal cells, thus providing MiRNA 
pharmacogenomics with strong clinical implications (Mishra et al., 2007; Calin et al., 2002; 
Hon & Zhang, 2007; Iorio et al., 2005). MiR-polymorphisms, in fact, have the potential to be 
employed predictors of drug response and may lead to the development of more accurate 
methods of determining appropriate drug dosage based on a patient’s genetic makeup, thus 
decreasing the likelihood of drug overdose (Russo et al., 2011; Mishra & Bertino, 2009). 
7.1.2 Other tools 
Other pharmacogenomic research areas are transcriptomics, metabonomics and proteomics.  
Transcriptomics is the study of gene transcripts, generally analyzed by cDNA expression 
microarrays which led to a number of exciting breakthroughs (Kieckle & Holland-Staley, 
2003; McGregor, 2003). This approach has the advantage to include all genes of potential 
importance and therefore, provides the possibility to identify new therapeutic and 
diagnostic targets. On the other hand, its main disadvantage is to be a non-targeted genome-
wide approach and therefore influenced by noise (i.e. expression signals of irrelevant genes) 
and increases the number of false positives (i.e. unimportant genes that are identified by 
chance) (Russo et al., 2011). Since acute lymphoblastic leukemia (ALL) is a ‘liquid’ tumour, 
relatively homogeneous and easy to isolate and characterize, it is ideal to assess global gene 
expression in cancer. Robust gene-expression profiling is a less labour-intensive and more 
automated alternative to the multiple methods that are currently used (e.g., 
immunochemistry, cytogenetics and molecular diagnostics), despite the possible limited 
availability of the appropriate source of sampling (e.g. blood, excreta, tissue), which is the 
major limitation of microarray studies (Armstrong et al., 2002; Golub et al., 1999; 
Ramaswamy & Golub, 2002; Moos et al., 2002; Ross et al., 2004). 
Metabonomics or metabolomics is the study of metabolite profiling (Plumb et al., 2002; Reo, 
2002). It has sampling limitations similar to transcriptomics, with one significant difference: 
metabonome represents an integrated response, in real time, to all endogenous plus all 
exogenous stimuli (e.g. drugs, chemical exposures, occupation, lifestyle, nutrition, age, 
gender) and it might offer the means to follow an individual patient’s phenotype—as a 
function of age, nutrition, course of disease, or therapy (Russo et al., 2011). Metabolomics 
and “liver profile” test can therefore be considered analogous, except that metabolomics also 
includes measurement of metabolites and thus provides greater sensitivity. It is true that 
metabolite profiling can be performed only on easily available samples, nonetheless this 
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approach may be regarded as an extension of the present practice of clinical pharmacology 
(Nebert et al., 2003).  
Proteomics is the study of all proteins encoded by the genome (Campbell & Ghazal, 2004) 
and has also been successful in certain areas of basic research. Although a recent study (Xing 
et al., 2004) estimated an average of 3.0 human proteins per gene, others have estimated that 
the true number of proteins per gene might be considerably higher (Russo et al., 2011). The 
limitation of proteomics—like transcriptomics and metabolomics—is represented by the 
types of source that must be sampled, e.g., blood, excreta or biopsy or tumour tissue in 
which relevant proteins exist.  
7.2 The need to use pharmacogenomics tools to develop paediatric medicines 
Recent data indicate that the general interest in the use of pharmacogenomics tools is 
increasing and in particular, it has been reported that today in some major companies up to 
90% of molecules reaching the clinical development stage are associated to a biomarker 
strategy (Scarpa et al, in press). 
The 35% of US approved drugs have pharmacogenetic information in their labels, and 
currently, 3 pharmacogenetic based drugs are licensed in the EU: herceptin (trastuzumab), 
glivec (imatinib mesilate) and erbitux (cetuximab). The marketing approved drug camptosar 
(irinotecan hydrochloride) is considered for re-labelling, based on post-approval research 
and the FDA decision to re-label the drug on the basis of the research’s results.  
Notwithstanding these considerable efforts and the claimed interest, the translation of 
‘omics’ results into clinical practices is apparently growing at a very disappointing rate; in 
particular, there is for example no consolidated source of information on industry activities 
with enough detail to allow accurate estimates. This gap is probably due to proprietary and 
patent issues, which prevent public disclosure of information (Scarpa et al, in press).  
In addition, it has been demonstrated that throughout the world more than 50% of the 
‘omics’ research is related to predisposition, i.e. the investigation of the correlation between 
genetic traits and the probability or susceptibility for a given pathology or disease, and this 
type of exploratory studies provide no insights into the mechanisms of the disease or the 
drug action, neither it can be used to improve medical practice or support therapeutic 
solutions. 
While many populations could take advantage from the introduction of ‘omics’ science 
aimed at developing personalised medicines, this approach could result of paramount 
importance particularly in ‘small populations’ for which the current trials approach, based 
on randomised controlled trials are not always applicable. Children represent the most 
significant example of such a case: in the paediatric field, in fact, few specific information are 
available because of the small number of patients and few resources invested to increase 
specific knowledge, and drugs are commonly used off-label or unlicensed and clinical trials 
result to be more difficult, longer and more expensive. 
As explained in other sections of this chapter, there is a tangible need to base paediatric 
trials on new methodological approaches that take into account the peculiarities of this 
population, providing at the same time the highest scientific evidence from each enrollable 
subject and protecting as much as possible the patients exposed to the trial.  
’Omics’ approaches, by definition, aim at capturing the essence of the developmental 
processes that characterize maturation from birth through to adulthood, a particularly 
appealing methodology for the paediatric research context. However, as explained for 
www.intechopen.com
 
Drug Development – A Case Study Based Insight into Modern Strategies 
 
618 
traditional research, it should be underlined that children should not be considered as small 
adults when they approach pharmacogenetic or pharmacogenomic studies. Many patterns 
of ontological development in the systems of the body illustrate how paediatric patients can 
differ from adults. Genotypes do not always correspond with expected phenotypes, making 
the exercise of deciding how to apply genomic research to paediatric medicine all the more 
complex (Scarpa et al, in press). 
7.3 Pharmacogenomics tools in the paediatric populations: State of the art 
Preliminary data on this issue have been provided within the context of the TEDDY 
Network of Excellence, an EU-funded project that dedicated a survey to the advancement of 
pharmacogenetic/pharmacogenomic application with the aim to explore the current status, 
limitations and perspectives of pharmacogenomic and pharmacogenetic clinical research in 
the paediatric population from an academic, regulatory and industrial perspective (Krekels 
et al., 2009). The main results reported by TEDDY showed that:  
 innovative PGx research in the paediatric field is ongoing, but generally suffers from a 
non-standardized methodology, and a scarcity of recognized source of data 
(databanking tailored for children) and industrial interest and funds; 
 few pharmaceutical companies declared ongoing pharmacogenomic- or 
pharmacogenetic-related research involving paediatric indications (Abbot, Altana 
Pharma, BD, Boherninger Ingelheim, Bristol-Myers Squibb, Ferring Pharmaceuticals, 
Genentech, GlaxoSmithKline, Isis Pharmaceuticals, Janssen-Cilag, Lilly, Merck, MGI 
Pharma Biologics, Novartis, Novo Nordisk, Roche, Sanofi Aventis, Servier, Taj 
Pharmaceuticals); 
 the translation of pharmacogenetics and pharmacogenomics into the clinic is very slow. 
In addition, often pharmacogenetic and pharmacogenomic studies show contradictory 
results that reflect inconsistent research methods, small sample sizes, no replication 
studies, non-standardized outcome measures, or little consideration of potential 
covariates such as co-morbidity.  
Pharmacogenetic studies in childhood conditions have been mainly developed in the 
following most common childhood conditions. 
7.3.1 Attention-deficit/hyperactivity disorder 
A multifactorial disorder characterized by physical hyperactivity and behavioural 
disinhibition, the attention-deficit/hyperactivity disorder (ADHD) usually appears during 
childhood or adolescence and often persists into adulthood. The usually prescribed psycho-
stimulant is methylphenidate (MPH) that presents an estimated 70% response rate in ADHD 
affected children (Elia et al., 1991; Spencer et al., 1996).  
According to pharmacogenetic studies, the inter-individual differences in stimulant-
response may be related to genetic influences (Kirley et al., 2003; Langley et al., 2005; Gilbert 
et al., 2006; Winsberg & Comings, 1999; Roman et al., 2002; Purper-Ouakil, 2008; Kereszturi 
et al, 2008; da Silva et al., 2008) and the search for candidate genes associated with ADHD 
focused on the catecholamine system. Genes associated with increased risk for ADHD are 
the dopamine transporter (DAT1) (Purper-Ouakil, 2008), the dopamine receptors (DRD4 
and DRD5) (Van Tol et al., 1992), serotonin transporter (5-HTT), and synaptosomal-
associated protein (SNAP-25) (Husain et al., 2007; Faraone et al., 2005; McGough et al., 2006). 
Other genes of potential interest in pharmacogenetic studies include catehol-O-
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methyltransferase (COMT) (Kereszturi et al, 2008 ), the adrenergic ┙2-receptor (ADRA2A 
and ADRA1A) (da Silva et al., 2008; Polankzyk et al., 2007; Elia et al., 2009) (Fig. 2). 
However, some pharmacogenetic studies show conflicting results. For example, in some of 
them individuals homozygous for the DAT1 10-repeat 480 bp-VNTR showed poorer 
outcome (Winsberg & Comings, 1999; Roman et al., 2002), whereas others report improved 
clinical outcome (Kirley et al., 2003) or no effect (Langley et al., 2005) on MPH response 
(Russo et al., 2011) (Fig. 2).  
7.3.2 Growth hormone deficiency  
GH deficiency (GHD) causing short stature is usually treated in children with GH 
replacement, carried out with fixed doses of human recombinant GH (hGH) adjusted for 
body weight or surface (Jorge et al., 2006).  
Two of the most common isoforms of GHR in humans are generated by retention (full-
length GHR, GHRfl) or exclusion of exon 3 (exon 3-deleted GHR, GHRd3) (Pantel et al., 
2000). These isoforms present a widespread distribution in humans, with the frequency of 
each allele ranging from 68–75% for GHRfl and 25–32% for GHRd3 (Pantel et al., 2000; Dos 
Santos et al., 2004) (Fig. 2). It has been demonstrated that, among children with idiopathic 
short stature or who were born small for gestational age, patients with at least one GHRd3 
allele presented 1.7 to 2 times more growth acceleration induced by hGH therapy than 
patients homozygous for the full-length isoform (Dos Santos et al., 2004). The study 
conducted by Jorge and colleagues demonstrated that patients carrying at least one GHRd3 
allele had a significantly better growth velocity in the first year of hGH replacement and 
achieved a taller adult height when compared with patients homozygous for GHRfl alleles 
(Jorge et al., 2006) (Fig. 2). 
7.3.3 Acute lymphoblastic leukemia  
Cancer chemotherapy is the therapeutic class that could benefit more from PGt and PGx: 
anticancer agents, in fact, are often given at doses near to those that produce toxicity, show 
wide inter-patient variability in disposition and effects, and should therefore be 
administered at optimal doses for the best chance of cure (Russo et al., 2011).  
In the USA, the leading cause of death by disease in children between 1 and 15 years of age 
is cancer and leukemia accounts for 33% of these deaths (Cheok & Evans, 2006). Twenty-five 
percent of all cancers in children is represented by Acute lymphoblastic leukemia (ALL). 
Treatment of ALL has undergone a significant progress, nonetheless long-term event-free 
survival rates are currently almost 80%, with 20% of patients who do not respond to 
standard therapy [Russo et al., 2011; Husain et al., 2007).  
Polymorphisms in genes encoding enzymes that metabolize chemotherapeutic agents can 
modify treatment response. The thiopurine methyltransferase (TPMT) genetic 
polymorphisms and mercaptopurine toxicity are one of the best-studied examples in 
pharmacogenetics. Although 23 variant alleles have been identified to date (Ujiie et al., 
2008), 3 variant alleles (TPMT*2 [Ala80Pro], TPMT*3A [Ala154Thr and Tyr240Cys] and 
TPMT*3C [Tyr240Cys]) account for >95% of low or intermediate TPMT enzyme activity: 
patients with TPMT deficiency are at very high risk of severe hematopoietic toxicity if 
treated with conventional doses of thiopurines (Cheok & Evans, 2006; Lennard et al., 1990; 
Yates et al., 1997). Patients who are heterozygous at the TPMT locus are at intermediate risk 
of dose-limiting toxicity and might require a modest dose reduction of approximately 35–
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50%, whereas TPMT-deficient patients require a dose reduction of >90% (Cheok & Evans, 
2006). Other important genes involved in ALL therapy are those codifying for the enzymes 
of the glutathione-S-transferase (GST) family. The polymorphisms of these genes have been 
associated with increased cancer incidence, therapy-related cancers and toxicity following 
chemotherapy (Cheok & Evans, 2006; Hayes et al., 2005). Polymorphisms of GSTM1, GSTP1, 
and GSTT1 exist in all populations. The GSTM1*0 (GSTM1 null) and GSTT1*0 (GSTT1 null) 
alleles represent deletions of GSTM1 and GSTT1 genes respectively and result in a loss of 
enzymatic activity (Rebbeck, 1997). The 1578 A > G transition in GSTP1 gives rise to the 
Ile105Val polymorphism, which confers reduced enzyme activity (Ye & Song, 2005); it is 
associated with high etoposide clearance in African-Americans treated with steroids (Kishi 
et al., 2004). Methotrexate (MTX) is also an important chemotherapeutic drug in the 
treatment of ALL. Methylenetetrahydrofolate reductase (MTHFR) is an essential enzyme in 
the folate/methotrexate metabolism pathway. About 10% of Caucasians show a genotypic 
variant of MTHFR (677 C >T; Ala222Val), which encodes a protein with about 30% of the 
wild-type activity (Frosst et al., 1995). This SNP has been linked to hepatotoxicity following 
methotrexate treatment (Ulrich et al., 2001). Another low-function variant of MTHFR results 
from the 1298 A >C (Glu429Ala) substitution; it has been reported to be protective for adult 
acute lymphocytic leukemia (Skibola et al., 1999; Wiemels et al., 2001) but not to altered 
effects of MTX in leukaemia (Krajinovic et al., 2004) (Fig. 2). 
7.3.4 Asthma 
The most common chronic disease among children, asthma affected in 2002 more than 30 
million individuals in the USA reported having been diagnosed as having asthma, including 
122 per 1000 children (Mattke et al., 2009). 
The response to shortacting albuterol therapy in children with asthma is influenced by a 
common polymorphism in the coding region of ADRB2 gene (Fig. 2). Bleecker and 
colleagues have recently showed no pharmacogenetics affect of this genetic variant on 
therapeutic response when the patients were treated with inhaled corticosteroids plus 
longacting ┚2-agonists (Bleecker et al., 2007).  
The other two modality of asthma treatment are corticosteroids and leukotriene modifiers, 
and polymorphisms of the genes (CRHR1, LTC4, ALOX5) involved in their modulation 
have been described (Fig. 2). In this example, the LTC4S -444 A>C promoter polymorphism 
has been associated to a reduced risk for asthma exacerbations when compared with 
individuals homozygous for reference allele (Sampson et al., 2000; Whelan et al., 2003; 
Husain et al., 2007); in other studies this observation was not consistent (Currie et al., 2003; 
Kedda et al., 2004) (Fig. 2). 
8. Pharmacovigilance: The need for ad hoc measures 
According to the World Health Organisation (WHO), pharmacovigilance is defined as “the 
science and activities relating to the detection, assessment, understanding and prevention of 
adverse effects or any other drug-related problem”.  
In adults pharmacovigilance predominantly refers to post-marketing surveillances.  
The situation is different in children. Because of the large extend of unlicensed and off-label 
drug uses and the small population numbers intensive monitoring of adverse events has to 
be performed before and after marketing authorisation.  
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Legend: ADHD=attention-deficit/hyperactivity disorder; ALL, acute lymphoblastic leukemia; GHD= 
growth hormone deficiency, SNP,=ingle nucleotide polymorphism; DIP=deletion/insertion 
polymorphism; VNTR=variable number tandem repeat; MPH=methylphenidate; MTX=methotrexate; 
MTXPG=methotrexate polyglutamate; HGVS=Human Genetic Variation Society; PMID=PubMed 
Identifier 
Fig. 2. Genetic polymorphisms in the most common childhood diseases (Russo et al. 2011) 
Adverse drug reactions (ADRs) in children differ from those manifested in adults in terms 
of frequency, nature and severity due to their distinct pharmacokinetics and 
pharmacodynamics (Kearns et al., 2003).  
There are also other issues to be considered with respect to the detection of adverse drug 
reactions in the paediatric population. Children can often not express their own drug 
therapy experience, which makes the determination of ADRs harder and takes more efforts 
and sensitivity towards the subject. The involvement of parents and carers therefore is even 
more important.  
8.1 Sample size considerations 
In the developed world, the paediatric population is small in general and relatively healthy 
when compared with for instance the elderly. Children and adolescents account for less than 
25% of the population of 0-80years old only. Thus, the number of patients needing a 
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treatment is always going to be smaller hence, the power to detect adverse drug reactions is 
far more limited.  
Furthermore, the paediatric population ranges from birth to the completion of the 18th year 
of age. With respect to the safety and efficacy of medicine, this cannot be seen as one 
homogenous population. Growth and development during these first years of life effect 
many physiological processes depending on age in different ways. This results in wanted 
and unwanted reactions to medicines that are not seen in adults and/or other paediatric 
sub-groups. To accommodate these differences the paediatric population has been sub-
classified by the ICH into different age groups (Table 2).  
 
  
< 37 weeks Pre-term neonates 
< 28 days newborn and neonates 
1months – 2years infants 
>2 - < 11years children 
>11 adolescents  
Table 2. Paediatric age groups according to ICH and EMA guidelines 
Developing medicines for children means that each age group needs to be studied 
separately. This poses another challenge, as certain numbers of participants are necessary in 
order to identify ADRs with statistical power. Many serious and severe ADRs are infrequent 
occurring in not more than 1 per 10,000 patients.  
Therefore, in paediatric pharmacovigilance methods, which can systematically capture large 
populations, are essential.  
8.2 Spontaneous reporting 
Spontaneous ADR reporting is the most common method in pharmacovigilance. It has been 
introduced after the Thalidomide scandal in the late 1960s. Today spontaneous reporting is 
part of the legal duties of health care professionals in many countries around the world.  
The system is well established and has many advantages but also disadvantages. 
Spontaneous ADR reporting is particularly useful for the detection of signals for new and 
unknown ADRs as it covers large populations, has low costs and is widely implemented.  
However, it cannot be used to study incidence and prevalence as there is a significant 
under-reporting and unknown denominators, i.e. size of the population exposed and 
therefore at risk for ADRs. Also it does not allow for an early detection as by the time ADRs 
are reported the outcome of the ADR is already established, hence there is no possibility of 
any intervention for the individual patient.  
Furthermore the data generated by the system are often biased because of both under-and 
over-reporting. The introduction of a drug to the market or promotion within the media 
may result in an increased awareness and thus increased reporting.  
The highest value of spontaneous reporting is signal detection is. However, to detect a 
signal a minimum number of case report is needed. For the spontaneous ADR reporting this 
ranges between 3 and 9 cases (Edwards et al., 1990). How fast this number of cases can be 
collected depends on various factors such as the number of users, the frequency of the ADR 
and the reporting rate. This means that compared to adults, for the relatively small 
population of children in different age groups it will take much longer to receive the 
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appropriate number of cases to identify signals. Reports for children with rare disease, or 
relating to drugs not commonly used, result in even lower reporting rates and hence may 
never be identified as potential safety signal. Therefore increasing the awareness of ADR 
reporting in the paediatric population and the compilation of ADR reports on an 
international basis is crucial to retrieve relevant and important information on adverse drug 
reactions.  
Despite all the limitations of spontaneous reporting, without the continuous reporting on 
suspicions of ADRs new hypothesis cannot be raised and consequently be tested by using 
other measures of pharmacovigilance. Therefore, spontaneous reporting will continue to be 
a crucial part in ADR reporting and efforts should be made to further improve it.  
8.3 Active ADR surveillance 
Stimulating clinicians and health care professionals regularly to report suspected ADRs and 
reminding them about the importance of reporting can significantly improve reporting 
rates. This may be a simple reminder sent on a weekly basis or the contribution of for 
instance pharmacists on the ward who will regularly ask for ADRs and document them 
accordingly. Furthermore tools can be made available to health care professionals which 
will make the reporting easier and also assure data collection is complete.  
Various pilot-projects were set up in the past and have shown the effectiveness of active 
ADR surveillance (Carleton et al., 2009; Clarkson et al., 2004; Menniti-Ippolito et al., 2000).  
Unfortunately resource limitations usually have not allowed to implement these in general 
practice.  
However, the results of these studies proof that if active surveillance is put in place the 
number of ADR reports significantly increases. Thus active ADR surveillance can help to 
overcome underreporting. Furthermore, active surveillance enables a more thorough data 
collection process and hence improved data quality. Establishing standardized 
methodologies can further improve and optimize the detection of ADRs.  
Overall, active pharmacovigilance poses an important feature in the pharmacovigilance 
process which particularly in the paediatric population should be utilized more and replace 
the simple standard of spontaneous reporting.  
8.4 Targeted ADR surveillance 
Targeted pharmacovigilance focuses on monitoring the safety profiles of specific drug 
groups in relation to specific ADRs. Depending on the set up it can reach large 
populations under observation and at the same time provide denominator data to allow 
for incidence calculations. The AMSP study in Germany has proven that targeted 
pharmacovigilance in psychiatry is a valuable tool for the evaluation of ADRs as well as 
educating clinicians in the field of ADRs (Grohmann et al., 2004). Another study from the 
UK determined the feasibility of conducting a prospective targeted pharmacovigilance 
study to monitor adverse drug reactions associated with atypical antipsychotic therapy in 
children (Rani et al., 2009).  
The projects showed that targeted pharmacovigilance can be very powerful but at the same 
time is resource intensive requiring a considerable amount of commitment from the 
participating clinicians including appropriate training. Nevertheless, the focused collection 
of practice based data is important. Methods accommodating all methodological issues still 
need to be developed using the continuously enhancing technological possibilities. The 
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payment of incentives or free access to all data collected during a surveillance could further 
enhance reporting.  
The potential of this method has been realized by various stakeholders such as the EMA and 
the Royal College of Paediatric and Child Health which recommend in their guidelines on 
the conduct for paediatric pharmacovigilance the use of "targeted pharmacovigilance" to 
monitor drug safety in children (CHMP, 2007b; Royal College of Paediatrics & Child Health, 
2004).  
8.5 Computerized ADR surveillance 
The use of computerized methods to improve the detection of adverse drug reactions in 
hospitalized patients is a promising approach in both paediatric and adult patients.  
Laboratory parameters outside the normal range or the change of such within a certain 
period of time would allow to generate signals which can inform the clinician that an ADR 
has potentially developed or may develop in a particular patient. A simple example is the 
decrease of potassium in a patient receiving medication impacting on potassium levels such 
as loop diuretics or beta-mimetics.  
Pilot studies have shown that such systems are feasible and the sensitivity is high. However, 
currently there is still a significant lack of specificity for those systems. The definition of 
rules is a particular challenge in the paediatric population as the normal ranges quickly 
change within different developmental stages (Haffner et al., 2005; Neubert et al., 2006).  
Another promising approach which has also been implemented on paediatric wards are 
“trigger tools”. Trigger tools use screening criteria to identify possible harm in a patient 
followed by an in-depth review of the patient chart for actual harm. The Canadian 
Association of Paediatric Health Centers Trigger Tool (CPTT) recently introduced the first 
validated comprehensive trigger tool to detect AEs in children hospitalized in acute care 
facilities (Matlow et al., 2011). Trigger tools do not solely report adverse drug reaction but 
also capture medication errors. With respect to medication safety in paediatric patients this 
is of importance; with respect to gaining effectively information on long-term safety 
outcomes there are clear limitations.  
8.6 Education and increasing awareness of ADRs  
The commitment and awareness of clinicians and other health care professionals involved 
with the paediatric patient is crucial for the detection and reporting of safety issues. This 
should be communicated early in the educational process and be part of the general 
training.  
The involvement of paediatric pharmacologists is important to improve the understanding 
of general principles of how drugs are acting. However, to date there are only a few experts 
specifically trained in this field.  
Within the recent activities around the paediatric drug development this need has been 
recognized. GRIP –Global Research in Paediatrics has been commissioned by the EU. One of 
its primary goals is the establishment of educational programmes in paediatric clinical 
pharmacology.  
In addition to health care professionals knowledgeable in paediatric pharmacology and 
pharmacovigilance families and carers have to be actively involved and encouraged to 
report adverse reactions. Especially in the paediatric population as children cannot express 
theirselves, parents and carers play an important rule. They are often very closed to the 
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children and get the impression of how the child feels and whether changes in behaviour 
and/or well-being could be related to drug therapy. This information may not be gathered 
from the responsible health care professionals.  
The new European regulation on pharmacovigilance supports this issues as it will allow that 
adverse drug reactions can be reported to the regulators and pharmaceutical companies by 
lay people such as patients, parents and carers.  
8.7 Conclusions 
In summary, pharmacovigilance is important in paediatric drug development. The need to 
further improve its methods has been realized by different stake holders including health 
care professionals and regulators. Various methods for ADR detection and reporting are 
available; to optimize ADR reporting in children a combination of methods needs to be 
used. Targeted pharmacovigilance is particularly to be promoted. It generates information 
on certain drugs or drug groups for short as well as long-term outcomes in large 
populations.  
In addition, training of health care professionals and increasing the awareness towards 
paediatric drug safety is a key element to generate a sustainable drug safety culture in 
paediatrics.  
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